
Insomnia
Insomnia
Last Section Update: 08/2025
Contributor(s): Shayna Sandhaus, PhD; Maureen Williams, ND
1 Overview
Summary and Quick Facts About Insomnia
- An estimated 10% of the global population experience chronic insomnia and more than 30% report sleep difficulties.
- In this protocol, you will learn about pharmaceutical sleep aids and the risks associated with their use. The efficacy and safety of several emerging therapies will also be discussed.
- Simple lifestyle strategies and nutrient supplements can improve sleep and help relieve insomnia.
- Melatonin plays a critical role in regulating sleep-wake cycles. Supplementation, at appropriate doses and with correct timing, has been shown to reduce insomnia symptoms in randomized controlled trials.
What Is Insomnia?
Insomnia is a common sleep disorder affecting approximately 10% of Americans. Insomnia can involve the inability to fall asleep (onset insomnia) or stay asleep (maintenance insomnia). Sleep deficiency not only diminishes quality of life, but it also increases risks of multiple health problems, such as anxiety, cardiovascular disease, and obesity.
Short-term insomnia can last several days or weeks, often in response to a stressful life event. Chronic insomnia, which lasts for three months or longer and affects sleep on three or more nights per week, can have profound long-term effects on health. Insomnia may arise without any clear underlying cause or may be related to a co-existing condition or medication.
Several natural interventions, such as melatonin and valerian, may help improve sleep and restore the body’s natural circadian rhythm.
What Are Causes and Risk Factors of Insomnia?
- Female gender—hormonal shifts from menstruation, pregnancy, and menopause can contribute to sleeping problems
- Advanced age
- Mental health problems, such as anxiety, depression, and bipolar disorder
- Physical health conditions, such as cardiovascular, urinary tract, and respiratory conditions
- Certain medications, such as decongestants, chemotherapy drugs, and beta-agonists
- Excess stress levels
- Irregular sleep habits, such as due to shift work
What Lifestyle and Non-Pharmacological Changes Can Be Beneficial for Insomnia?
- Improving “sleep hygiene”
- Minimize light and noise
- Avoid large meals before bedtime
- Avoid bedtime activities not related to sleep
- Sleep restriction therapy, which limits the amount of time spent in bed
- Cognitive-behavioral therapy
- Relaxation therapies
What are Conventional Medical Treatments for Insomnia?
- Over-the-counter drugs, such as antihistamines for occasional use
- Benzodiazepines, such as alprazolam (Xanax), clonazepam (Klonipin), and diazepam (Valium) for short-term use
- Benzodiazepine-like drugs, such as zaleplon (Sonata), zolpidem (Ambien), and eszopiclone (Lunesta) for short-term use
- Antidepressants with sedative properties, such as doxepin (Silenor), trazodone (Desyrel), and amitriptyline (Elavil)
What Are Novel and Emerging Therapies for Insomnia?
- Dual orexin receptor antagonists like suvorexant (Belsomra) promote sleep by blocking wakefulness-promoting neuropeptides from binding to their receptors.
- Drugs that target melatonin receptors (MT1 and MT2), such as ramelteon (Rozerem), may induce sleep by mimicking melatonin.
- 5-HT2 serotonin receptor antagonists may increase deep sleep.
- Short-term use of the anesthetic drug propofol may help reset sleep rhythms.
What Natural Interventions May Be Beneficial for Insomnia?
- Melatonin. Melatonin is a hormone that is highly correlated with the body’s sleep-wake cycle. Low melatonin levels have been linked to insomnia in the elderly. Supplementation may help improve sleep.
- L-tryptophan. L-tryptophan is a precursor to melatonin and serotonin. Supplementation with L-tryptophan may increase melatonin production to aid sleep and may help alleviate some forms of depression.
- Magnesium. Magnesium helps regulate the body’s circadian rhythm. A study showed supplementation with magnesium, zinc, and melatonin improved sleep in elderly subjects.
- Zinc. Higher zinc levels in the body may be correlated with longer periods of sleep. Oral administration of zinc can improve sleep quality and duration.
- Valerian. Valerian is a sedative herb that has been used since ancient times to treat insomnia. A study comparing valerian supplementation to a commonly prescribed tranquilizer found comparable efficacy.
- Ashwagandha. Ashwagandha is an herb shown in several animal models to reduce stress and anxiety and improve sleep. Human trials indicate ashwagandha may decrease stress and anxiety, but further research is needed.
- Lemon balm. Lemon balm has been shown to improve mood and feelings of calmness. Lemon balm, alone or in combination with valerian, may also improve sleep and symptoms of insomnia.
- Lavender. Aromatherapy with lavender essential oil may improve sleep quality and reduce feelings of drowsiness after waking.
- Natural interventions that promote relaxation. These include honokiol, glycine, chamomile, passion flower, and bioactive milk peptides.
- Nutrients that reduce nocturia (the need to urinate at night). These include beta-sitosterol, lycopene, Pygeum africanum, Lindera aggregata, Crataeva nurvala, and Equisetum arvense.
2 Introduction
Insomnia is defined as difficulty falling or staying asleep, dissatisfaction with sleep, and daytime impairment due to sleep loss.1 Worldwide, about 10% of people have chronic insomnia and more than 33% report getting insufficient sleep.2 Roughly 20% of Americans reportedly experience occasional insomnia and another 10% struggle with an insomnia disorder.3 People with medical, psychiatric, and substance use disorders, as well as the elderly, women, and those in low-income households, are especially prone to insomnia.1
Observational research shows seven to eight hours of sleep per night is optimal for health.4 Sleep is essential for learning and memory formation, emotional well-being, physical growth and development, immune function, and cardiovascular health. Sleep is also integral to cellular repair processes, helps regulate insulin levels, and normalizes appetite signaling. Sleep deficiency can dramatically diminish a person’s quality of life. Insufficient sleep also increases risks of health problems, such as cardiovascular disease, depression, and obesity.5-9
Insomnia is associated with such symptoms as not feeling well-rested after waking, daytime fatigue, irritability, depression or anxiety, excessive uneasiness about sleep, difficulty performing school or work tasks, and increased risk of accidents, especially involving an automobile.10
Despite the major toll insomnia takes, conventional treatment options remain far from ideal. For instance, popular hypnotics (also known as sedatives or “sleeping pills”), such as zolpidem (Ambien), eszopiclone (Lunesta), and temazepam (Restoril), have been consistently associated with significantly increased risk of serious adverse events, including death.11-13 This highlights the need for safe and effective strategies to improve sleep quality, especially as up to 10% of U.S. adults use hypnotics.13
In this protocol, you will learn about the causes of sleep problems and simple lifestyle changes that can improve your sleep.14,15 You will also discover emerging therapies that have achieved prolonged improvements in insomnia with potentially fewer side effects than some popular sleep drugs.16 In addition, you will read about several natural compounds that modulate sleep biology and may be safer than pharmaceutical treatment options.
3 Defining Insomnia
Insomnia disorders are defined as persistent difficulty falling or staying asleep, waking earlier than desired, inability or resistance to going to bed at an appropriate time, or requiring an intervention to fall asleep. They are further characterized by at least one daytime impairment, such as1:
- Physical and/or mental fatigue
- Sleepiness
- Cognitive problems
- Social, family, school, or workplace dysfunction
- Behavioral problems
- Low energy or motivation
- Tendency to make more errors or experience accidents
- Concern about or dissatisfaction with sleep
A person who has experienced such sleep problems and daytime impairments at least three times per week for at least three months can be diagnosed with chronic insomnia, whereas less persistent insomnia is considered short-term. Finally, if these problems can be attributable to other circumstances or causes, such as noise, discomfort, medical or psychiatric issues, medications, or substance use, they fall under the category of “other insomnia disorders.”1,2
4 Diagnosing Insomnia
To diagnose insomnia, a healthcare professional will take a detailed history to determine whether the patient’s symptoms match the criteria for insomnia disorder (described above). A sleep questionnaire or sleep diary may be useful if the diagnosis is uncertain.17
Insomnia disorder is a diagnosis based exclusively on subjective information.17 Physical exam and lab tests can be used to determine whether an underlying medical issue is likely to be a contributing factor. It is important to note that insomnia frequently co-occurs with other health conditions, including other sleep disorders, and should be considered an independent disorder unless it can be fully attributed to another cause.1 Actigraphy, which involves the use of an unobtrusive worn device to measure limb movements over time, may be useful for providing information about sleep phase, duration, pattern, and efficiency (the amount of time in bed spent sleeping). Polysomnography, sometimes referred to as a sleep study, is performed in a sleep lab and measures brain waves, breathing, heart rate and rhythm, muscle activity, and eye movements during sleep. Polysomnography is only recommended if other sleep disorders, such as sleep apnea or parasomnias (eg, sleepwalking or nightmares), are suspected.17,18
5 Risk Factors
The following factors have been associated with increased insomnia risk19:
- Older age
- Female gender
- Family history of insomnia
- Other mental health, physical health, or sleep condition(s)
- Stress
- Physical inactivity
- Use of certain medications, such as stimulants
- An irregular sleep schedule
- Using electronic devices close to bedtime
Importantly, research is increasingly showing that links between insomnia and other health and sleep problems are frequently bi-directional; in other words, either condition may contribute to the other.2
Gender and Hormones
Women are more likely to struggle with insomnia than men, and changes in levels of female hormones (estrogen and progesterone) that occur with menstrual cycling, pregnancy, and the menopausal transition are thought to play a role.20,21 Almost 60% of postmenopausal women suffer from insomnia, and therapies targeting menopausal symptoms, including hormone therapies, can improve sleep.22,23
Sleep disorders have been linked to lower testosterone levels in both men and women. In a cohort study of more than 1,300 men age 65 and older, subjects with lower testosterone levels had lower sleep efficiency (the percentage of time spent asleep while in bed) and increased night waking, although this association was largely explained by a higher rate of overweight and obesity among those with lower testosterone.24,25 Low testosterone levels may also worsen sleep quality, which may improve with moderate levels of testosterone replacement therapy.26
Lower serum testosterone levels are correlated with increased obstructive sleep apnea severity.27,28 Obstructive sleep apnea is most common in middle-aged men, especially those who are overweight. People with obstructive sleep apnea have increased night waking, fragmented sleep, reduced sleep efficiency, and less rapid eye movement (REM) sleep, which in turn may lower testosterone levels.25 More research is required to understand causal relationships between sleep quality and testosterone levels, especially in older or obese individuals and those with chronic health conditions.
Psychological Health
Insomnia can be a symptom of and contributor to many mental health problems, including anxiety, depression, schizophrenia, attention deficit hyperactivity disorder, and bipolar disorder.39-41
Patients with untreated insomnia are two to 10 times more likely to experience new or recurrent episodes of depression. A longitudinal study of people age 65 and older in Japan found a statistically significant bi-directional relationship between insomnia and the development of depression.42 Studies indicate insomnia is also bi-directionally related to anxiety disorders and substance use disorders.43,44 In one longitudinal study in adolescents, insomnia symptoms were associated with the use of alcohol, cannabis, illegal drugs, and suicidal ideation and attempts.45 Insomnia is also linked to certain personality traits, such as social introversion and the repression of feelings.46
One randomized controlled study in 30 healthy subjects age 21–30 found emotional reactivity to unpleasant images increased after one night of total sleep deprivation compared with a night of normal sleep in a sleep lab, which suggests that sleep may be important for emotional regulation.47 In another controlled study, 22 people with chronic insomnia disorder and 38 healthy sleepers underwent an MRI scan during an emotional regulation task in which they were shown emotionally positive, negative, or neutral imagery, some of which was related to insomnia. Those with insomnia showed higher levels of activity in the amygdala (the emotional processing area of the brain) when shown images related to insomnia. Furthermore, during a second viewing of the images, healthy sleepers displayed habituation (dulled amygdala responses) but those with insomnia reacted inconsistently.48
Psychophysiological insomnia is a common type of chronic insomnia that can be very difficult to treat. It appears to be linked to increased activity in the “thinking” area of the brain, experienced as arousal, when going to bed. Psychophysiological insomnia is associated with excessive worrying at bedtime, specifically focused on not being able to sleep.49 Afflicted individuals have a hard time relaxing when they go to sleep, resulting in racing thoughts. They often focus on their difficulty falling asleep, which results in more anxiety that further disturbs sleep.
Over time, poor sleep and worries about sleeping can become associated with going to bed, resulting in a pattern of chronically poor sleep that affects daytime activities. Some believe that, in addition to heightened arousal, individuals with psychophysiological insomnia may have some dysfunctional neurological inhibitory mechanisms that would normally help the mind "disengage" from daytime thought patterns.50
Treatment of psychophysiological insomnia includes good sleep hygiene practices, no daytime napping, limiting caffeine intake, cognitive behavioral therapy, and approaches that acknowledge worries (such as journaling or making a worry list). A recent longitudinal case series study with 60 subjects found that co-occurring psychiatric disorders were strongly linked to negative treatment outcomes for people with psychophysiological insomnia, and people with strong social support and cognitive coping skills were most successful in treatment.51
Medical Conditions
Certain medical conditions can disrupt sleep, increasing the risk of insomnia. These include chronic pain conditions, asthma and other respiratory diseases, cardiovascular disease, gastrointestinal issues, urinary tract disorders, thyroid disease, and cancer.2,52-54
Nocturia is defined as the need to urinate one or more times during the night.55 It not only reduces sleep quality, but also increases the risks of falling and mortality, particularly in the elderly.55,56 Nocturia can be a symptom of a medical condition, such as chronic kidney disease, diabetes, high blood pressure, congestive heart failure, chronic obstructive pulmonary disease, metabolic syndrome, or lower urinary tract problems such as prostate enlargement or overactive bladder.55,57 In some cases, nocturia is due to polyuria (excessive urine production) at night.57 Estrogen depletion after menopause is associated with increased risk of insomnia and nocturia in women, and treatment with hormone therapy can improve both conditions.58 Some evidence indicates nocturia can also be caused by circadian dysregulation, suggesting a circular relationship between nocturia and insomnia.59,60 A 2025 systematic review and meta-analysis of seven studies involving 5,396 older adults found nocturia was almost twice as prevalent in those with insomnia than in healthy sleepers, and insomnia treatment appeared to reduce nocturia.61
Insomnia can also be a symptom of another underlying sleep disorder, such as sleep apnea or restless leg syndrome. Restless leg syndrome is a condition in which a person feels discomfort in the legs and a strong urge to move them. These urges can be strongest when trying to fall and stay asleep.62
Age
Insomnia symptoms have been reported to occur in 30–48% of older adults, and up to 20% have an insomnia disorder. Age-related changes in circadian rhythms and sleep architecture, particularly reduced REM and deep sleep, contribute to diminished sleep efficiency and decreased total sleep time from an average of 6.5–8.5 hours during young adulthood to 5–7 hours in those over 60 years of age.63
Losing sleep may also be a contributor to aging. An analysis of data from the Women’s Health Initiative determined insomnia symptoms were associated with increased biological age, as measured by changes in DNA methylation in blood cells. Insomnia symptoms were also correlated with detrimental changes in immune cell balance.64
Medications and Stimulants
Many prescription medications can disrupt normal sleep patterns and contribute to insomnia and sleepiness, and research shows their use is increasing.65,66 Medication-induced insomnia can be caused by a wide variety of drugs, including decongestants, diuretics, antihistamines, monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), corticosteroids, chemotherapeutic agents, calcium channel blockers, beta-agonists, and theophylline.67-70 Some over-the-counter medications, such as energy-boosting and weight-loss products, may contain stimulants that contribute to insomnia.71 If you think a medication may be disrupting your sleep, speak with your healthcare provider.
Caffeine
Caffeine is one of the most widely consumed stimulants in the world. Found most commonly in coffee, tea, and some soft drinks, caffeine is used to combat sleepiness and enhance performance. Stimulants make it harder for the brain to achieve the state of relaxation needed for sleep.
The half-life (ie, amount of time it takes the body to break down 50% of a dose) of caffeine is between three and seven hours. Larger amounts and/or repeated doses of caffeine slow caffeine clearance, causing the effects to last even longer.72 As a result, caffeine consumption can impair sleep for many hours. In a national survey that evaluated caffeine consumption and difficulty falling and staying asleep, amount of non-restorative sleep, daytime sleepiness, and typical duration of sleep attained per night, caffeine consumption was associated with insomnia symptoms, especially daytime sleepiness.73
Another review of randomized controlled trials and epidemiological studies found caffeine prolonged sleep latency (ie, the amount of time it takes to fall asleep), reduced total sleep time and sleep efficiency, and worsened perceived sleep quality.74 Older adults may be more sensitive to the effects of caffeine. Most research suggests mild caffeine consumption in the morning does not impair sleep.75
Nicotine and Smoking
The use of tobacco or nicotine replacement therapy, as well as nicotine (eg, smoking) withdrawal, can contribute to insomnia.76 One study analyzed 29 years of data from the Children and Adults in the Community Study to assess the prevalence of insomnia among heavy/continuous smokers, late-start smokers, occasional smokers, quitters/decreasers, and non-smokers. The study found chronic smokers were more likely to develop insomnia symptoms later in life.77 Another review of data from more than 83,000 people in the Behavioral Risk Factor Surveillance System indicated current smokers or smokeless tobacco users were twice as likely to have insufficient sleep as non-smokers and non-smokeless tobacco users, independent of age, sex, race, alcohol use, and body mass index (BMI). Secondhand smoke exposure was also associated with insufficient sleep among people who never smoked or who quit.78
Alcohol
While most people think of alcohol as a sedative, it increases dopamine release within the brain, which has a stimulating effect.79 Chronic alcohol use is associated with insomnia, as is alcohol withdrawal.80 A review of more than 60 studies indicated two to three drinks before bed may promote sleep, but this effect diminishes after three continuous days.81 Sleep disturbances are common among those who abuse alcohol and are often associated with relapse.82 A study examining the prevalence of insomnia in 302 alcohol-dependent patients in a treatment program in Poland found more than 60% had symptoms of insomnia, with delayed sleep being the most common symptom. A history of childhood abuse, poor health, and severity of alcoholism were predictors of insomnia in this group.83
A longitudinal outcomes study including 267 subjects with alcohol-dependence issues found that, at baseline, 47% of subjects were classified as having insomnia. Abstaining from or reducing alcohol intake reduced reported sleep disturbances, although insomnia persisted in 60% of cases, particularly in those with severe insomnia. Alcohol treatment programs should include insomnia evaluation during the treatment period to help focus care and prevent relapse.84
More information is available in Life Extension’s Alcohol: Reducing the Risks protocol.
Stress
People under stress often struggle with insomnia.85 Worries about finances, work, school, and family issues may cause a state of hyperarousal, making it difficult to relax into a restful sleep state. One observational study found those who were prone to cognitive and emotional hyperarousal were more likely to experience stress-related insomnia.86 Stress can also decrease sleep quality.87 Major life events, such as job loss, moving, the birth of a child, death of a loved one, or divorce, may also trigger a bout of insomnia.
Working Unusual Shifts
Not all U.S. employees have a traditional 9 a.m. to 5 p.m. job. Nearly 10% of those with a non-standard work schedule (such as rotating shifts, on-call work, or permanent night shifts) have shift-work disorder, which is a disconnect between the body's circadian rhythm and the earth’s natural day-night cycle.88 An additional 30% of shift workers experience such symptoms as excessive sleepiness when they need to be awake and alert, insomnia, problems focusing, lack of energy, and depression. Even shift workers who get enough sleep during the day may experience some of these symptoms, as their internal clock sends signals to indicate it is time to sleep during nighttime hours.89 Shift work may also be associated with increased risk of certain diseases, including cancer and heart disease.
6 Complications of Insomnia
Sleep is important for overall health and well-being, and chronic insomnia can have serious mental and physical health consequences. People with insomnia not only report a lower quality of life, but may also struggle with poor job and school performance, a higher rate of automobile accidents, and greater risks of several diseases, including heart disease, some cancers, and immunological conditions.90
A prospective study that followed nearly 5,000 people for 11 years concluded insomnia was associated with a greater risk of cardiovascular disease.91 Another prospective study that followed nearly 55,000 people for 13 years found people with multiple insomnia-related symptoms had a higher risk of heart failure.92 A study of nearly 4,000 subjects found those with a very short sleep duration (ie, less than six hours of sleep per night) were more likely to have subclinical atherosclerosis than those who slept six to seven, seven to eight, or more than eight hours per night. In addition, those with more fragmented or interrupted sleep had more areas of atherosclerotic plaque.93
Sleep is also influenced by, and has an influence on, the immune system. A lack of sleep can impair immunity, leaving individuals more susceptible to viral, bacterial, and parasitic infections.94 Research indicates sleep deficiency is associated with decreased immune function and increased levels of inflammatory markers, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), which promote inflammation.95
Steroid hormones and sleep are also bi-directionally connected: Hormones can influence sleep and insomnia can affect the endocrine system.94,96 Insomnia has been associated with elevated levels of cortisol, epinephrine, and other stress hormones.97-99 Furthermore, sleep deprivation may contribute to the development of metabolic disorders, including poor blood glucose control and obesity.96,100,101
Insomnia has been associated with chronic pain and musculoskeletal issues. A controlled study of 34 people, half with insomnia and half without, found those with insomnia experienced pain twice as often as those without. The insomnia group had more frequent and intense pain, more sensitivity to heat and pressure, and a dysfunctional pain inhibition system.102 Researchers concluded that sleep quality is associated with the regulation of pain processing and ability to modulate pain. In a crossover study involving 14 healthy subjects who underwent a night of total sleep deprivation and a night of habitual sleep, researchers found that a night of sleep deprivation resulted in increased levels of sleepiness, anxiety, and sensitivity to heat and pressure.103
Researchers continue to investigate the potential relationship between inadequate sleep and risk of dementia. In a large observational study, researchers retrospectively evaluated people over 20 years of age with no preexisting dementia who were part of a national health insurance research database in Taiwan. The study gathered data on dementia incidence from 92,079 people with non–apnea-related sleep disorders and compared them with 92,079 healthy controls. During the time between January 2000 and December 2011, the incidence of dementia was 4.19 per 1,000 person-years in the group with sleep disorders and 2.95 per 1,000 person-years in the healthy group.104 In another study, 6,284 Americans who were aged 65 years and older and dementia free at baseline were followed from 2011 until 2020. After adjusting for demographic and health factors, having difficulties falling asleep did not affect dementia risk, but using sleep medications was associated with an 8% increase in dementia risk.105 Surprisingly, this study also found those whose insomnia involved trouble falling back to sleep after waking early in the morning had a 40% lower risk of dementia, even after fully adjusting for other factors. One proposed explanation was that these individuals may have spent more time doing social or physical activities, which helped maintain or replenish cognitive reserve. These results suggest greater complexity to the potential relationship between insomnia and dementia risk.
7 Treating Insomnia: Non-pharmacological Therapies
Non-pharmacological interventions have been shown to improve sleep quality in patients with insomnia. These treatment options include cognitive behavioral therapy, sleep restriction, sleep hygiene, and relaxation therapy.106
Improving Sleep Hygiene and General Lifestyle Considerations
Sleep hygiene is a behavioral approach to promoting sleep. It involves such habits as having a regular bedtime routine and a consistent sleep-wake schedule, getting regular exercise, maintaining a relaxation or meditation practice, and limiting eating, drinking, and light exposure before bed.107 One meta-analysis of 15 clinical trials found sleep hygiene improved sleep in patients with insomnia, though it was less effective than cognitive behavioral therapy.108
A prospective cross-sectional analysis of 548 college students examined the relationship between sleep hygiene and insomnia severity. Students reported inconsistent sleep-wake cycles and frequent worrying in bed. Improper sleep scheduling, uncomfortable sleep environments, and engaging in behaviors that create hyperarousal before bed were associated with insomnia severity. After controlling for other risk factors, sleep scheduling was most strongly associated with insomnia severity.109 Another analysis of 130 patients admitted to a hospital burn unit found that a nurse-driven sleep hygiene protocol was successful in helping patients fall asleep more quickly and experience fewer sleep disruptions.110
Consider the following sleep hygiene and general lifestyle measures90,111,112:
- Keep your bedroom cool, dark, and quiet.
- Keep sleep and wake times consistent throughout the week.
- Avoid eating large meals two to three hours before bed.
- Limit stimulant intake (eg, caffeine, nicotine, and alcohol) during the day, especially close to bedtime.
- Limit daytime sleep.
- Spend time outdoors in natural light each day.
- Engage in daily physical activity but avoid vigorous exercise during the two hours prior to sleep.
- Create bedtime rituals (eg, taking a warm bath and listening to soft music) to improve relaxation.
- Reduce stress. People with insomnia should also review the Stress Management protocol.
- Use the bedroom for sexual activity and sleep only and avoid other activities, such as watching TV or reading, in the bedroom.
- If worrying about the time keeps you awake, cover the alarm clock.
Sleep Restriction to Reset Circadian Rhythms
Sleep restriction therapy limits time in bed (including naps) to increase the biological need for sleep at night. This process usually begins by restricting time in bed to the estimated amount of time one should spend sleeping. For example, a person who stays in bed for nine hours but only sleeps six will initially restrict time in bed to six hours. This causes mild sleep deprivation in the beginning, but the sleepiness it creates trains the body to fall asleep more quickly. As the body adjusts, people can extend time spent in bed by 15 to 20 minutes until they are able to get a full night of sleep without spending extra time in bed.113
A study comparing sleep hygiene therapy plus sleep restriction to sleep hygiene therapy alone found sleep restriction improved sleep efficiency.113,114 A review of evidence for sleep restriction as a stand-alone treatment for insomnia found it improved sleep efficiency and total sleep time, and researchers concluded it was an effective means of treating chronic insomnia.115
Cognitive Behavioral Therapy
In 2016, the American College of Physicians recommended that cognitive behavioral therapy be the initial treatment protocol for patients with chronic insomnia.116 Cognitive behavioral therapy helps people develop behaviors more conducive to sleep by teaching the subject to change their beliefs about sleep, develop good sleep habits, and improve their sleep environment. Traditionally, it involves regular visits to a clinician who will assess sleep patterns and work to change how the patient gets to sleep. However, self-help cognitive behavioral therapy programs have become increasingly available and may be similarly effective.117
Cognitive behavioral therapy for insomnia typically includes other modalities, such as sleep restriction, sleep hygiene, and relaxation training.117,118 It may also incorporate biofeedback training or stimulus control. Biofeedback training uses a device to monitor and provide feedback about particular biological functions, such as respiration, heart rate, and/or muscle contractions, to help a person make subtle changes (such as consciously slowing breathing rate or relaxing muscles) to modulate nervous system activity. Biofeedback may help individuals better manage such conditions as anxiety, pain, and insomnia. Stimulus control focuses on removing factors associated with sleep resistance, such as an inconsistent bedtime or using the bedroom for activities other than sleep.118
Cognitive behavioral therapy has been shown to be an effective treatment for insomnia disorders.119-122 A randomized controlled trial that followed 36 people for six months suggests cognitive behavioral therapy improved insomnia severity scores, sleep measures, and dysfunctional sleep beliefs.123 A systematic review concluded cognitive behavioral therapy may be more effective than benzodiazepine and non-benzodiazepine drugs for long-term treatment of insomnia.124 Other research suggests cognitive behavioral therapy decreases depression, improves mental health, and is more effective in treating insomnia than hypnotic sleep aids.12,125
Relaxation Therapy
Some patients with insomnia have high levels of cognitive and physiological arousal, as evidenced by increased cerebral metabolism of glucose. Relaxation therapies (including meditation, visualization techniques, breathing exercises, and progressive muscle relaxation) aim to achieve a more relaxed state prior to bedtime. Most of these techniques can be self-administered after some initial guidance from a medical professional.106
Social support, stress reduction techniques (including meditation and yoga), and improving coping skills for dealing with stress may be useful ways to combat insomnia in some people.126 Research involving 30 adults with insomnia found that mindfulness-based stress reduction, including meditation training, resulted in significant improvements in sleep quality, time needed to fall sleep, and total sleep time.127 Another study of 44 postmenopausal women age 50‒65 who were not undergoing hormone replacement therapy found practicing yoga for four months lowered insomnia and stress severity scores and improved quality of life.128
8 Treating Insomnia: Pharmacologic Treatment
There are many pharmacological treatment options for insomnia, including over-the-counter medications, benzodiazepines, non-benzodiazepines, and antidepressants.63 These medications are generally intended for occasional, intermittent use.
Over-the-Counter Medications
Over-the-counter (OTC) medications are frequently recommended for occasional use to promote a good night’s sleep. Antihistamines that block H1 receptors (also known as first-generation antihistamines), such as doxylamine (Unisom) and diphenhydramine (Benadryl), are among the most widely used OTC sleep medications, although there is little research to support their use for this purpose.129 Blocking H1 receptors reduces congestion, sneezing, coughing, and allergy symptoms. It also causes sedation through effects on the central nervous system. Their ability to cause drowsiness and sedation has led to their use as sleep aids.130
There are few rigorously designed trials to definitively determine the efficacy and safety of OTC sleep aids.131 In addition to common side effects, such as dry mouth and constipation, diphenhydramine can cause drowsiness the day after use.132 Importantly, some people may develop a tolerance or dependence to these medications, and they may cause dangerous side effects when used with other medications. In addition, if taken for a long time and then stopped, they may worsen sleep problems.129
Antihistamines should be used with caution, especially in older individuals, due to increased risk of falling and confusion and a propensity to interact with other drugs.132 One review found 50‒65% of older adults misused OTC sleep medications. Drug-drug interactions and drug-age interactions were most common.133 In 2015, the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults recommended individuals over age 65 not use products containing the ingredients diphenhydramine and doxylamine.134
Speak with a physician prior to using a sleep aid to ensure it does not interact with any medications you currently take or affect conditions you have. In addition135:
- Avoid alcohol, which causes additional sedation.
- Do not engage in activities that require being alert after taking the medication, such as driving a vehicle.
- If you find you need sleep medication for longer than two weeks, contact your healthcare provider.
Benzodiazepines
Benzodiazepines (eg, alprazolam [Xanax], clonazepam [Klonopin], and diazepam [Valium]) were the cornerstone for treatment of insomnia until the 1990s. These medications enhance effects of the neurotransmitter gamma-aminobutyric acid (GABA)—one of the main inhibitory neurotransmitters in the brain—by binding to multiple brain receptor sites.136 Studies have found benzodiazepines enhance sleep onset, reduce the number of nighttime waking, and improve total sleep time and sleep quality with short-term use.63 They are generally recommended for short-term (up to four weeks) use, but longer use may be appropriate in some circumstances.1
Benzodiazepines can be classified based on their duration of action. Short-acting benzodiazepines are more likely to cause withdrawal symptoms, whereas long-acting ones are more likely to leave users feeling groggy.136 A longitudinal cohort study of more than 200 nursing home residents in Belgium found long-term use of benzodiazepines actually decreased sleep quality over the course of one year, compared to people who did not use these medications. This suggests chronic use of these drugs does not maintain a high sleep quality.137
Non-benzodiazepines
Non-benzodiazepines, also called benzodiazepine-like drugs, such as zaleplon (Sonata), zolpidem, zopiclone (Imovane), and eszopiclone, act on fewer brain receptors than benzodiazepines and therefore have different side effects than benzodiazepines. As with benzodiazepines, their recommended use is limited to four weeks or less, although long-term use is common.1 Zaleplon, one of the first non-benzodiazepines developed for the treatment of insomnia, has been proven effective in reducing the amount of time it takes to fall asleep. Its short half-life (1 hour) also reduces the risk of lasting effects the following morning, which may make it less useful for people who wake up during the night. Older adults should not take zaleplon because it is not as safe or effective as other medications available.63
Note while using zaleplon, some individuals experienced sleep disturbances, such as getting out of bed and engaging in such activities as driving cars, having sex, or consuming food, while partially asleep. These people were typically unable to remember what had happened the next day. Also, a person’s mental health may change unexpectedly while using this medication, including increases in aggressiveness, hallucinations, memory problems, depression, confusion, and suicidal ideation. Zaleplon should only be taken under the direction and observation of a healthcare professional.
Zolpidem's half-life (about 2.5 hours) may make it more effective at reducing the amount of time it takes to fall asleep and aid in staying asleep while causing less residual daytime sleepiness.63 A literature review found 10 mg of zolpidem in adults and 5 mg in those age 65 years and older reduced sleep latency and increased sleep duration in people with insomnia. Residual daytime effects are not common, as long as the individual is in bed for at least eight hours before waking for the day.138 Zolpidem clears more slowly in women than men. Morning blood levels may be higher, which may affect psychomotor performance. In 2013, the Food and Drug Administration (FDA) required manufacturers to lower the recommended dose from 10 mg to 5 mg for immediate-release preparations and from 12.5 mg to 6.5 mg for extended-release forms.63
Eszopiclone has also been shown to be effective at improving sleep.139,140 This medication lengthens total sleep time and helps people fall asleep more quickly. It takes longer to work than other non-benzodiazepines but also lasts longer. In 2014, 10 years after eszopiclone’s approval, the FDA lowered the recommended starting dose to 1 mg due to risk of next-day impairment to driving, memory, and concentration. A double-blind study involving 91 people between ages 25 and 40 demonstrated that 3 mg eszopiclone was associated with psychomotor and memory impairment from 7.5 to 11 hours after dosing. Doses may be increased to 2‒3 mg under physician guidance, but 3 mg is associated with a state of altered mental awareness.141
Antidepressants
As many people with depression also struggle with insomnia, antidepressant medications may help relieve symptoms of both conditions. In addition to relieving depression, some antidepressants have a sedating effect and most have no addictive properties.132 Furthermore, most sedating antidepressants do not appear to harm sleep architecture.144 Therefore, antidepressants are sometimes prescribed as a treatment for insomnia, even in patients without depression. Notably, the use of antidepressants is often on an off-label basis; that is, at the discretion of the treating physician even if the drug is not specifically approved to treat insomnia.1,132
Doxepin (Silenor) is an H1 histamine receptor antagonist with tricyclic antidepressant properties. It is sometimes prescribed to treat insomnia because of its sedative properties.63 Doxepin has been found to increase sleep time without causing significant adverse effects and is the only antidepressant that is FDA approved for treating insomnia.132,145,146 Research has indicated low doses (<10 mg) of doxepin can improve sleep onset, sleep maintenance, early morning waking, and sleep duration and quality over a 12-week period.132,146,147
Trazodone is a serotonin modulator used to treat major depressive disorders and has a mild sedative effect. Some research shows it may temporarily help people fall asleep and may be effective for short-term management of insomnia.148,149 Trazodone can cause side effects, such as dizziness, postural low blood pressure, heart arrhythmias, and daytime sleepiness.132 In a double-blind, placebo-controlled, crossover trial, 16 insomniacs were given 50 mg trazodone nightly for one week and placebo nightly for one week, in random order. Trazodone reduced nighttime waking and improved sleep quality, but also resulted in small but significant impairments in short-term memory, verbal learning, and arm muscle endurance.150 Researchers concluded its risks may outweigh its benefits, particularly in elderly individuals.63,150 In a randomized, double-blind, placebo-controlled trial involving 30 Alzheimer disease patients, individuals who took 50 mg trazodone once daily for two weeks slept 42.5 minutes more per night and had no increase in daytime sleepiness or cognitive impairment compared with placebo.151
Amitriptyline, a sedating antidepressant that alters brain chemistry to stabilize mood, is sometimes used to treat insomnia. Importantly, amitriptyline has been shown to increase suicidal thoughts in individuals under age 24 years. There are no controlled trials evaluating amitriptyline for insomnia in the absence of other medical conditions.149
Other drugs that are sometimes used to treat insomnia include mirtazapine (Remeron), a tetracyclic antidepressant, and quetiapine (Seroquel), an atypical antipsychotic drug. Limited clinical research has indicated mirtazapine may improve sleep parameters. Until more is known, it is not recommended for insomnia patients without depression.132 In patients with psychotic disorders, quetiapine is associated with a range of serious long-term side effects, including metabolic disturbance, muscle movement disorders, and heart rhythm irregularity. Although lower doses are typically used to treat insomnia, quetiapine’s safety as a sedative is still uncertain, and there is little clinical evidence for its efficacy at improving sleep.152,153
A 2017 review of published literature on antidepressants and sleep found low dosages of these drugs administered early at night (prior to bedtime) as part of an intervention that also involves behavioral treatments, such as cognitive behavior therapy, lead to best results.144
Dual Orexin Receptor Antagonists
Orexins are neuropeptides produced by neurons in the brain’s hypothalamus. Newly discovered in 1998, orexins have now been shown to play an important role in promoting arousal and wakefulness through interactions with two types of receptors, known as orexin receptor 1 and orexin receptor 2.154 Orexins are also involved in brain pathways related to appetite, reward, fear, and cognition.155 Orexin deficiency causes a type of narcolepsy. Narcolepsy is a condition characterized by excessive daytime sleepiness, sudden loss of muscle tone triggered by strong emotions, sleep paralysis, brief hallucinations while falling asleep or waking, and disrupted nighttime sleep. Excess or dysregulated activation of the orexin/orexin receptor system has been linked to sleep fragmentation and insomnia, as well as acute stress and stress-related disorders.154,156
Dual orexin receptor antagonists (DORAs) are an emerging class of drugs that improve sleep by inhibiting orexin receptors 1 and 2. DORAs appear to affect sleep architecture by increasing REM sleep while causing no change, or a decrease, in non-REM sleep.157 DORAs have been shown to improve sleep in patients with insomnia, and researchers are currently exploring their possible role in treating neurological and psychiatric conditions associated with insomnia, such as Alzheimer disease, Parkinson disease, depression, and bipolar disorder.158-160
In 2014, suvorexant (Belsomra) became the first drug in this class to receive FDA approval for the treatment of insomnia resulting from difficulty initiating or maintaining sleep.154 This approval was based on randomized controlled trials showing suvorexant improved subjective and objective measures of time to sleep onset and total sleep time, as well as subjective sleep quality. A 2017 systematic review found that excessive sleepiness, fatigue, and abnormal dreams were the most common side effects.154,161 The FDA has since approved two other DORAs: lemborexant (Dayvigo) in 2019 and daridorexant (Quviviq) in 2022.154
A meta-analysis that included findings from eight randomized controlled trials involving 5,198 adult subjects with insomnia compared the safety and efficacy of suvorexant, lemborexant, and daridorexant. All three drugs, at all doses tested, were more effective for the studied outcomes than placebo. Insomnia severity scores improved similarly with each of the three drugs. The analysis showed that all the studied medications and dosages were associated with some excessive daytime sleepiness, except for the 50 mg dose of daridorexant. Unlike benzodiazepines, DORAs did not increase the likelihood of dizziness or falls in people with insomnia.162 Other meta-analyses have shown DORAs were associated with increased risks of excessive daytime sleepiness, fatigue, dry mouth, headache, upper respiratory symptoms, and sleep paralysis.163-165
9 Novel and Emerging Treatments
Targeting Melatonin Receptors
Melatonin is a hormone involved in controlling the body’s sleep-wake cycle. Melatonin activates two receptors, MT1 and MT2. These receptors are found mainly in a region of the brain that controls circadian rhythms but are also present in other parts of the body. Supplementing with melatonin modulates central nervous system activities by activating MT1 and MT2 receptors.167 Drugs that stimulate these receptors, known as melatonin receptor agonists, mimic melatonin by binding to and activating the same receptors, inducing sleep. Although these drugs are not identical to melatonin supplements, they have been shown to help improve sleep in insomnia patients.132
Ramelteon (Rozerem) is an FDA-approved insomnia medication that binds to and activates MT1 and MT2 melatonin receptors.168 Rather than depressing the central nervous system, ramelteon promotes sleep by regulating the sleep-wake cycle.169 It is highly selective for the melatonin receptors MT1 and MT2, which minimizes its potential to cause side effects and has a half-life of just over one hour.141,170-172 Ramelteon has been reported to cause side effects, such as dizziness, sleepiness, fatigue, and headache. It can be used long term without causing dependence or withdrawal symptoms.132,169
In a study of adults age 65 and older, ramelteon significantly reduced sleep latency over five weeks with no significant side effects.173 In another randomized, double-blind, placebo-controlled trial in adults age 18‒64, subjects who received 8 or 16 mg of ramelteon had reductions in sleep latency and sleep onset.174
Tasimelteon (Hetlioz) is a high-affinity MT1-MT2 receptor agonist that regulates sleep and shifts circadian rhythms. It was originally developed to treat non–24-hour sleep-wake disorder, in which individuals cannot train the body clock to the 24-hour dark-light cycle. In one placebo-controlled clinical trial in healthy individuals, tasimelteon reduced sleep latency and increased sleep efficiency with no side effects.175
Animal research has demonstrated that the melatonin receptor MT2 promotes deep sleep. Drugs that specifically target the MT2 receptor are beginning to emerge, including IIK7 and UCM765. Animal research suggests these medications increase amount of deep sleep and reduce sleep latency in mice.176,177 However, further human research is needed to confirm safety, efficacy, and potency.178
5-HT2 Receptor Antagonists
5-HT receptors, 5-HT2A and 5-HT2C, are of particular interest with regard to sleep. Activation of these receptors interferes with deep sleep.181 Therefore, therapeutics that reduce signaling through these receptors to facilitate high-quality sleep are being developed. While both animal and human data suggest blocking 5-HT2A/C signaling appears to be a promising mechanism for improving sleep quality, more research is needed.183,184
Serotonin (5-hydroxytryptamine or 5-HT) is a neurotransmitter that plays a role in regulating sleep, appetite, thermoregulation, emotion, and cognition.179 It acts by binding to and activating various 5-HT receptors in the ventrolateral preoptic nucleus (VLPO), the main structure of neurons that trigger non-REM sleep.180,181 Impairments in 5-HT transmission have been linked to depression, anxiety, and sleep disorders. In one study, 5-HT-deficient mice demonstrated a disrupted sleep-wake cycle with an increase in restless sleep (a period of sleep with frequent wakings).182
In animal research, sleep-promoting neurons in the VLPO can be characterized by their response to neurotransmitters, such as noradrenaline and 5-HT. Those inhibited by 5-HT are known as Type 1 neurons and those excited by 5-HT are known as Type 2. Type 2 neurons are involved in sleep initiation and triggering activation of Type 1 neurons. Type1 are thought to be responsible for sleep maintenance through inhibition of the brain’s arousal system.179
10 Nutrients
Melatonin
Melatonin, a hormone made in the brain’s pineal gland, is a major regulator of the body's sleep-wake cycle. The pineal gland’s release of melatonin into the bloodstream peaks in the evening, coinciding with nighttime darkness, and falls in the morning, stimulated by the onset of daylight. Melatonin is also produced in a number of other tissues, where it helps synchronize local circadian rhythms.187
Low melatonin levels have been linked to insomnia, particularly in the elderly. In a clinical review, serum melatonin levels were reported to be significantly lower and the time of peak melatonin values delayed in elderly subjects with insomnia compared with age-matched healthy controls.188 A meta-analysis of 19 randomized placebo-controlled trials including 1,683 patients found that melatonin supplementation improved sleep quality, increased total sleep time, and decreased sleep latency.189,190 Other studies suggest it may enhance alertness after sleep191 and reduce the number of times people wake up during the night.192 Melatonin may also improve nocturia, a condition closely related to insomnia. A systematic review reported melatonin or melatonin receptor agonist therapy improved nocturia in eight of nine clinical trials.193
While melatonin has been found to improve sleep quantity and quality, questions persist about optimal timing and dose. A 2024 systematic review that examined findings from 26 randomized controlled trials yielded several important findings194:
- Melatonin had a stronger effect in healthy subjects than in those diagnosed with insomnia.
- Sleep latency gradually decreased and total sleep time increased as the dose of melatonin increased from 0.5 mg, with peak effects seen at 4 mg per night (higher doses did not result in additional benefit).
- Taking melatonin earlier in the night (longer before going to bed) enhanced its effect on sleep latency and total sleep time. The greatest benefit was seen at 3–3.5 hours prior to bedtime, the longest interval for which there was evidence.
The enhanced effect of a three-hour lead time for melatonin supplementation may be related in part to its synchrony with normal patterns of melatonin secretion, since, in healthy adults, levels of endogenous melatonin have been observed to peak about two hours before sleep.194-196
These findings suggest the potential benefits of melatonin may be underestimated because of typical sub-optimal dosing (1–2 mg) and timing (30–60 minutes before bedtime) recommendations. Clinical trials are needed to determine whether optimal dosing and timing may improve melatonin’s efficacy in insomnia patients. However, the aforementioned analysis does provide a rationale for individuals who have tried melatonin (taken shortly before bedtime) without success to try again with dosing about three hours before bedtime.
Nobiletin
Circadian rhythms are biological processes that vary during the natural 24-hour day-night cycle. Maintaining consistent and healthy circadian rhythms promotes overall health and well-being, including healthy sleep patterns.197,198
The human body contains two regulatory elements that respond to circadian rhythms: the central clock and peripheral clocks.199 Melatonin supplementation can help modulate the central clock. Nobiletin, a flavonoid derived from citrus peels, helps modulate peripheral clocks.200,201
Preclinical research suggests nobiletin may protect against metabolic syndrome and age-related health deterioration in part by helping regulate peripheral clocks. When given to obese mice, nobiletin counteracted metabolic syndrome and increased energy expenditure.201 Another animal study demonstrated that nobiletin reduced symptoms of delirium in mice. Researchers believe the mechanism of action involves regulating the expression of the proteins that help maintain a stable circadian rhythm.202 Nobiletin may also help alleviate circadian rhythm disorders and jet lag.203
L-tryptophan
L-tryptophan is an amino acid that serves as a precursor for serotonin and melatonin.204,205 L-tryptophan supplements may increase the amount of melatonin made by the pineal gland, leading to better sleep.206 L-tryptophan has long been of interest in the sleep field. Research dating back more than 44 years found that 1 gram reduced the amount of time needed to fall asleep.207 Like melatonin, L-tryptophan levels decrease with age208; therefore, L-tryptophan supplementation may aid in the treatment of insomnia in the elderly.
One animal study found tryptophan supplementation helped prepare the body for sleep by reducing core body temperature and enhancing rest at night. It also lowered levels of IL-6, an inflammatory cytokine.206 In one small human clinical trial, intravenous infusion of L-tryptophan caused dramatic increases in plasma melatonin levels and had a sleep-inducing effect, regardless of whether it was administered in the daytime or nighttime.209 In addition, L-tryptophan may help alleviate some forms of depression, which can exacerbate insomnia.210
An analysis of data from the National Health and Nutrition Examination Survey (NHANES) (2001‒2002) involving more than 29,000 individuals determined higher tryptophan intake was associated with longer sleep duration.211 Another study examined whether consumption of cereal grains fortified with tryptophan improved the sleep-wake cycle in 35 individuals age 55‒75 years. The study compared the effects of three diets, each followed for three weeks: usual diet; a diet that included standard cereal grains, eaten at breakfast and dinner, providing 22.5 mg tryptophan per 30 grams; and a diet that included enriched grains providing 60 mg tryptophan per 30 grams. Eating tryptophan-enriched cereal grains was found to increase sleep efficiency and total sleep time and decrease sleep fragmentation and latency.212
Another randomized study involving 33 male college students investigated the effects of tryptophan consumption at breakfast and daytime light exposure on melatonin secretion and sleep. Subjects ingested either a tryptophan-poor meal paired with dim light, tryptophan-rich meal with dim light, tryptophan-poor meal and bright light, or tryptophan-rich meal with bright light exposure for four days. The combination of bright light and a tryptophan-rich meal at breakfast resulted in the greatest evening rise in melatonin levels.213
Glycine
Glycine, a non-essential amino acid, also acts as a quieting neurotransmitter and helps support bone health, digestion, and metabolism.214 In one randomized, single-blind, crossover trial in 11 healthy volunteers, 3 grams glycine one hour before bedtime led to shortened time to sleep onset and improved sleep satisfaction without next-day sleepiness.215 In a randomized, double-blind, crossover trial, 3 grams glycine before bedtime improved sleep quality and next-day fatigue.216 In a randomized, single-blind, crossover trial, 10 healthy men underwent experimental sleep restriction to 75% of usual and were given 3 grams glycine before bed for three nights and placebo for three nights, in random order. Glycine was found to improve performance on memory, cognition, and reaction-time tests and self-rated fatigue and sleepiness levels compared with placebo.217
Magnesium
Magnesium is a mineral that plays a role in cellular communication, energy production, muscle function, blood sugar maintenance, and regulation of circadian rhythms.218 The recommended dietary allowance (RDA) for magnesium is 420 mg for men and 320 mg for women age 31 and older.219
Magnesium is needed for healthy sleep regulation.220 Magnesium deficiency is associated with shorter sleep duration221 and may cause inflammation, which could result in conditions associated with poor sleep, including diabetes and cardiovascular disease.222 In addition, research suggests intracellular magnesium concentrations decline as sleep restriction increases.223
One clinical trial found magnesium supplementation helped relieve insomnia related to restless legs.224 In a double-blind placebo-controlled clinical trial, 43 patients in long-term care with chronic insomnia were given 5 mg melatonin, 225 mg magnesium, and 11.25 mg zinc or placebo one hour before bedtime every night for eight weeks. The treatment group saw improved sleep quality and improved quality-of-life measures compared with placebo.225
A form of magnesium known as magnesium L-threonate may be beneficial for sleep, as it penetrates the blood-brain barrier more efficiently than other forms of magnesium.226,227
Zinc
Zinc, a trace element that is essential for many biological functions, including immune health and neurocognition, may help reduce the risk of inflammatory diseases.228 According to a literature review, higher serum zinc levels have been linked to healthy sleep duration and quality, and supplementing with oral zinc may increase both amount and quality of sleep.229 One randomized controlled trial found zinc, along with magnesium and melatonin, reduced insomnia.225 An observational study in which blood and hair levels of zinc and copper were measured in 126 women found those with the highest blood and hair zinc-to-copper ratios were more likely to have optimal sleep duration than women with the lowest zinc-to-copper ratios.230 In an animal study, mice fed a yeast extract containing zinc had increased levels of non-REM sleep and decreased motor activity levels when sleeping.231
How zinc supports sleep patterns remains unclear, but some researchers speculate that oral administration of zinc rapidly increases blood levels, crosses the blood-brain barrier, and activates signaling pathways involved in circadian regulation and sleep induction.229
Valerian
Valerian (Valeriana officinalis) is a perennial flowering plant that has been used traditionally for treating sleep problems, anxiety, and stress.232 Valerian root contains several compounds with sedative effects, including valerenic acid and valepotriates. Valerian root is believed to increase the activity of gamma aminobutyric acid, or GABA, the body’s main quieting neurotransmitter.233,234
In one randomized, triple-blind, controlled trial involving 100 postmenopausal women struggling with insomnia, treatment with 530 mg valerian root for four weeks resulted in improved sleep quality.235 An animal study found a mixture of hops and valerian improved sleep parameters, including total sleep time, by modulating GABA signaling.236
One study involving 202 patients with insomnia found 600 mg valerian per day for six weeks showed comparable efficacy to a commonly prescribed hypnotic (oxazepam).237 A review of relevant studies indicated valerian had a favorable safety profile, no known interactions with common medications, and could be recommended as an option for people struggling with sleep issues.238 The typical dose of valerian is about 300‒600 mg, 30 to 120 minutes before going to sleep.239 It may take up to two weeks of daily use for the full sedative effect of valerian to manifest.240
Valerian may also be useful when applied topically. One randomized clinical trial involving 85 severely ill patients found that acupressure with valerian between the hours of 7:00 p.m. and 10:00 p.m. resulted in increased sleep time and less frequent night awakenings.241
Chamomile
Chamomile (Matricaria chamomilla) is a popular herb often used as a tea to promote sleep and relaxation.242,243 The dried flower extracts of chamomile contain terpenoids and flavonoids that may reduce inflammation and help treat insomnia, ulcers, wounds, pain, and muscle spasms. Sedative properties of this herb are believed to be due to certain flavonoids that may modulate benzodiazepine-receptor signaling in the brain.244
One randomized, placebo-controlled, double-blind study involving 57 people with a history of anxiety and depression found that chamomile supplementation reduced depressive symptom scores.245 In a randomized controlled trial of 80 postnatal women, drinking chamomile tea for two weeks helped alleviate symptoms of depression and improve sleep quality.246 In a randomized controlled trial, 200 mg chamomile twice daily for 28 days improved sleep quality in a group of elderly subjects.247 In another clinical trial of 77 elderly subjects, 400 mg chamomile twice daily improved reported sleep quality measures.248 One randomized placebo-controlled clinical trial found 270 mg chamomile twice daily for 28 days improved daytime functioning of 34 subjects with sleep problems.243
Passionflower
Passionflower (Passiflora incarnata) has long been used to treat anxiety and insomnia in Europe.249 The active compounds in passionflower appear to interact with the GABA and opioid systems.250-252 Extracts of this plant have shown sedative, anti-diabetic, and anti-asthmatic activities in preclinical research.249
In one randomized double-blind trial involving 78 subjects with insomnia, an herbal combination containing hops, valerian, and passionflower was shown to improve sleep time, sleep latency, and night awakenings similarly to treatment with the hypnotic drug zolpidem after two weeks.253 One randomized study compared supplementation with either passionflower or St John’s wort in 59 women with menopausal symptoms experiencing sleep disturbances and depression. After six weeks, both groups demonstrated improved sleep quality.254 In an animal model, passionflower was shown to reduce anxious behavior.251 Another animal study found that passionflower-derived compounds prevented dependence on the benzodiazepine diazepam when given with the drug over a three-week period.255 While this extract has a good safety profile, more rigorous clinical data is necessary to assess its efficacy in humans.
Ashwagandha
Ashwagandha (Withania somnifera) is an Indian herb used for centuries as a wellness-promoting tonic. Ashwagandha may be beneficial for reducing anxiety, promoting calmness, and treating insomnia. This herb has been best characterized for its effects on stress. A randomized, double-blind, placebo-controlled trial in 64 individuals struggling with chronic stress found 300 mg of an ashwagandha extract twice daily for 60 days reduced reported stress and serum cortisol levels.256
Several animal studies have found that this extract improved the ability to handle stress and reduced anxiety.257-259 In vitro research suggests a component of this herb, withanone, protects nerve cells from oxidative stress.260,261 Because emotional stress can be a significant contributor to insomnia, ashwagandha may help indirectly improve sleep by improving the response to stress.
In a randomized, double-blind, placebo-controlled trial, 144 subjects with non-restorative sleep took 120 mg of a standardized ashwagandha extract or placebo once daily for six weeks. Those who took ashwagandha reported a 72% increase in sleep quality versus a 29% increase in those who took placebo. Moreover, the group taking ashwagandha had improved sleep efficiency, total sleep time, and sleep latency, as well as quality of life scores.262
Ashwagandha has also been found to directly improve sleep in animal models. In one animal study, sleep-deprived rats given an ashwagandha extract showed improvements in behavioral tests, indicating the supplement may help mitigate the cognitive and memory impairments associated with insomnia. The rats also had decreased signs of cellular stress and apoptosis (programmed cell death) in the hippocampus, the brain region involved in memory, emotions, and behavior.263-265
Lemon Balm
Lemon balm (Melissa officinalis) is an herb from the mint family traditionally used for its calming and anxiety-reducing effects.266,267 One randomized, double-blind, placebo-controlled, crossover study with 18 healthy participants showed a single 600 mg dose of lemon balm improved mood and significantly increased self-rated calmness one hour later, following a 20-minute set of stress-inducing tasks.268 Lemon balm has also been investigated for the treatment of sleeping problems.
Research indicates rosmarinic acid, ursolic acid, and oleanolic acid are the active compounds in lemon balm, with rosmarinic acid being responsible for most of the activity associated with this herb. Lemon balm may inhibit the breakdown of the neurotransmitter GABA.269 In a randomized, controlled, crossover trial in 11 healthy people, taking a lemon balm extract providing 500 mg rosmarinic acid per day for seven days was found to be safe and tolerable.270
In an open-label prospective study, 20 individuals with indications of stress took a standardized lemon balm extract for 15 days. Improvements in anxiety and insomnia symptoms were reported.271 In a randomized placebo-controlled trial, 100 postmenopausal women with sleep disorders received a combination of valerian and lemon balm. The treatment group experienced a reduction in sleep disorder symptoms.235 An uncontrolled study in 918 children with restlessness and difficulty sleeping found tablets with 160 mg valerian and 80 mg lemon balm, taken at doses of up to two tablets twice daily for at least four weeks, improved symptoms in 81% of participants.272
Lavender (as essential oil aromatherapy)
Aromatherapy is an alternative medicine practice that utilizes plant oils to treat health problems. Lavender oils have been extensively studied for the treatment of insomnia. A randomized controlled clinical trial involving 79 college students with sleeping difficulties found that inhaled lavender combined with good sleep hygiene practices was more effective than sleep hygiene alone in improving sleep quality.273 In another trial, 67 middle-age women with insomnia were randomized to either inhale lavender oil for 20 minutes twice weekly for 12 weeks or participate in a control group receiving sleep hygiene education. The treatment group experienced an improved quality of sleep compared with the control group.274
In a four-week study involving 28 postpartum women struggling with anxiety and depression, subjects were either randomized into a group that inhaled a blend of rose otto and lavender essential oils or instructed to avoid essential oil use during the study period. The aromatherapy group had significant improvements in depression and anxiety scores, with no adverse side effects reported.275 A single-blind randomized controlled trial in 15 healthy Japanese students found exposure to lavender oil aroma for five days reduced self-reported sleepiness on waking.276 In an animal model, lavender oil use for seven days reduced behaviors associated with depression and anxiety. Exposure to the oil also has been shown to decrease aggressive behaviors and improve social interactions.277
Oral lavender may also help combat sleep problems. In a multi-center, randomized, double-blind trial, six weeks of treatment with oral lavender oil (Silexan) was found to be as effective as the benzodiazepine lorazepam for reducing anxiety and improving sleep, without causing sedative side effects, in patients with generalized anxiety disorder.278
Lavender is thought to possess antioxidant abilities and reduce inflammatory pathways. It also may alter ion channels in neurotransmitter junctions, which suggests it may be beneficial in Alzheimer disease patients. The oil may act via the limbic system to quiet the central nervous system when absorbed through the skin after topical application. While lavender oil appears safe and tolerable, and evidence supporting its use is promising, more clinical trials with long-term data are required to further clarify its role in promoting sleep and relaxation.277
Saffron
Saffron, a spice derived from the Crocus sativus flower, has been widely used as a flavoring agent and traditionally used to treat depression and asthma. It has powerful antioxidant properties, and preclinical studies indicate its major active compounds safranal, crocin, and crocetin may have anti-tumor and anti-atherosclerotic properties.279 Animal and in vitro research suggest saffron may have a role in treating Alzheimer disease, cardiac ischemia, and age-related macular degeneration.280 Other preclinical studies indicate saffron and crocin may have neuroprotective properties.281
Preliminary evidence suggests saffron may promote sleep. Animal studies on safranal indicate it may support non-REM sleep and decrease sleep latency.282 One placebo-controlled human trial examined the effect of 300 mg of saffron on sleep quality in 50 diabetic patients. After one week, sleep quality improved in the treatment group.283 However, more high-quality human data is necessary to determine if and how saffron can be used to treat insomnia.
Honokiol
Honokiol is a lignan (a type of fiber) extracted from the bark, seeds, and leaves of the Magnolia tree. It has traditionally been used to treat mood disorders, including anxiety and depression,284 and is believed to have anti-tumor, anti-inflammatory, and antioxidative effects.285 It can cross the blood-brain barrier, resulting in enhanced bioavailability, and research suggests it enhances GABA receptor activity in the brain’s hippocampus and exerts neuroprotective effects in the central nervous system.286,284
In one animal study, mice given honokiol experienced shortened sleep latency and increased non-REM sleep.287 Several older studies with animal models support these findings, including one in which mice given seven daily treatments of two different traditional plant-based tinctures (Hangekobokuto and Saibokuto) had reduced anxiety and improved maze tests scores. These effects appeared to be related to the honokiol content, as varying the chemical content of the samples still produced similar results as long as honokiol was contained in the sample, and honokiol-free preparations were not effective.288 Mice administered 20 mg/kg honokiol showed reduced anxiety levels with no reduction in motor function during a maze test.289 Another animal study demonstrated that honokiol had similar anxiolytic effects as diazepam, but appeared not to cause amnesia and dependence.290 While these results are promising, more human clinical trials are required to understand how honokiol affects sleep.
Danshen
Danshen (Salvia miltiorrhiza) is an herb traditionally used to promote sleep and enhance blood circulation, thus improving cardiovascular health.291 The main components of S. miltiorrhiza include rosmarinic acid and salvianolic acid. It is often used in combination with borneol for better pharmacological results.292 Early animal research suggests danshen has anxiety-relieving properties.293 However, well-designed clinical data is lacking, and adequate research must be carried out to understand how danshen alters sleep.
Bioactive Milk Peptides
Certain peptides derived from the enzymatic breakdown of milk proteins may relieve stress-related sleep disorders. These peptides are believed to act on GABA receptors in the brain, inducing relaxation and sleep. In one study, these bioactive peptides increased time spent sleeping and reduced the amount of sleep needed after just two weeks of treatment. Another randomized, double-blind, placebo-controlled study of 63 women found 150 mg daily of the milk protein alpha-s1 casein hydrolysate reduced stress-related symptoms, including sleep difficulties.294,295
2025
- Aug: Updated section on medical conditions in Risk Factors; Added section on dual orexin receptor antagonists to Treating Insomnia: Pharmacologic Treatment; Added section on nutrients targeting urinary frequency and urgency to Nutrients
2023
- Dec: Updated section on Complications of Insomnia
2021
- Oct: Updated section on ashwagandha in Nutrients
2019
- May: Comprehensive update & review
Disclaimer and Safety Information
This information (and any accompanying material) is not intended to replace the attention or advice of a physician or other qualified health care professional. Anyone who wishes to embark on any dietary, drug, exercise, or other lifestyle change intended to prevent or treat a specific disease or condition should first consult with and seek clearance from a physician or other qualified health care professional. Pregnant women in particular should seek the advice of a physician before using any protocol listed on this website. The protocols described on this website are for adults only, unless otherwise specified. Product labels may contain important safety information and the most recent product information provided by the product manufacturers should be carefully reviewed prior to use to verify the dose, administration, and contraindications. National, state, and local laws may vary regarding the use and application of many of the therapies discussed. The reader assumes the risk of any injuries. The authors and publishers, their affiliates and assigns are not liable for any injury and/or damage to persons arising from this protocol and expressly disclaim responsibility for any adverse effects resulting from the use of the information contained herein.
The protocols raise many issues that are subject to change as new data emerge. None of our suggested protocol regimens can guarantee health benefits. Life Extension has not performed independent verification of the data contained in the referenced materials, and expressly disclaims responsibility for any error in the literature.
- Ferini-Strambi L. Insomnia disorder. Minerva Med. Aug 2025;116(4):309-322. doi:10.23736/S0026-4806.25.09690-9. https://www.ncbi.nlm.nih.gov/pubmed/39932761
- Georgiev T, Draganova A, Avramov K, Terziyski K. Chronic insomnia - beyond the symptom of insufficient sleep. Folia Med (Plovdiv). May 16 2025;67(3)doi:10.3897/folmed.67.e151493. https://www.ncbi.nlm.nih.gov/pubmed/40524581
- Morin CM, Jarrin DC. Epidemiology of Insomnia: Prevalence, Course, Risk Factors, and Public Health Burden. Sleep medicine clinics. Jun 2022;17(2):173-191. doi:10.1016/j.jsmc.2022.03.003. https://www.ncbi.nlm.nih.gov/pubmed/35659072
- Hirshkowitz M, Whiton K, Albert SM, et al. National Sleep Foundation's sleep time duration recommendations: methodology and results summary. Sleep health. Mar 2015;1(1):40-43. doi:10.1016/j.sleh.2014.12.010. https://www.ncbi.nlm.nih.gov/pubmed/29073412
- Terauchi M, Hiramitsu S, Akiyoshi M, et al. Associations between anxiety, depression and insomnia in peri- and post-menopausal women. Maturitas. May 2012;72(1):61-5. doi:10.1016/j.maturitas.2012.01.014. https://www.ncbi.nlm.nih.gov/pubmed/22326659
- Ohayon MM, Caulet M, Lemoine P. Comorbidity of mental and insomnia disorders in the general population. Comprehensive psychiatry. Jul-Aug 1998;39(4):185-97. doi:10.1016/s0010-440x(98)90059-1. https://www.ncbi.nlm.nih.gov/pubmed/9675502
- Kakizaki M, Inoue K, Kuriyama S, et al. Sleep duration and the risk of prostate cancer: the Ohsaki Cohort Study. British journal of cancer. Jul 8 2008;99(1):176-8. doi:10.1038/sj.bjc.6604425. https://www.ncbi.nlm.nih.gov/pubmed/18542076
- Verkasalo PK, Lillberg K, Stevens RG, et al. Sleep duration and breast cancer: a prospective cohort study. Cancer Res. Oct 15 2005;65(20):9595-600. doi:10.1158/0008-5472.CAN-05-2138. https://www.ncbi.nlm.nih.gov/pubmed/16230426
- Phillips B, Mannino DM. Do insomnia complaints cause hypertension or cardiovascular disease? Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. Aug 15 2007;3(5):489-94. https://www.ncbi.nlm.nih.gov/pubmed/17803012 https://pmc.ncbi.nlm.nih.gov/articles/PMC1978336/
- Mayo Clinic. Insomnia treatment: Cognitive behavioral therapy instead of sleeping pills. Updated 4/5/2023. Accessed 6/26/2025, https://www.mayoclinic.org/diseases-conditions/insomnia/in-depth/insomnia-treatment/art-20046677
- Kripke DF. I petitioned the FDA to restrict hypnotics: here is why. Sleep Med. Jul 2016;23:119-120. doi:10.1016/j.sleep.2015.12.011. https://www.ncbi.nlm.nih.gov/pubmed/26924532
- Kripke DF. Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit. F1000Research. 2016;5:918. doi:10.12688/f1000research.8729.3. https://www.ncbi.nlm.nih.gov/pubmed/27303633
- Kripke DF, Langer RD, Kline LE. Hypnotics' association with mortality or cancer: a matched cohort study. BMJ open. 2012;2(1):e000850. doi:10.1136/bmjopen-2012-000850. https://www.ncbi.nlm.nih.gov/pubmed/22371848
- Yang CM, Lin SC, Hsu SC, Cheng CP. Maladaptive sleep hygiene practices in good sleepers and patients with insomnia. Journal of health psychology. Jan 2010;15(1):147-55. doi:10.1177/1359105309346342. https://www.ncbi.nlm.nih.gov/pubmed/20064894
- Lande RG, Gragnani C. Nonpharmacologic approaches to the management of insomnia. J Am Osteopath Assoc. Dec 2010;110(12):695-701. https://www.ncbi.nlm.nih.gov/pubmed/21178150
- Xu Z, Jiang X, Li W, Gao D, Li X, Liu J. Propofol-induced sleep: efficacy and safety in patients with refractory chronic primary insomnia. Cell Biochem Biophys. Jul 2011;60(3):161-6. doi:10.1007/s12013-010-9135-7. https://www.ncbi.nlm.nih.gov/pubmed/21107748 https://link.springer.com/article/10.1007/s12013-010-9135-7
- Holder S, Narula NS. Common Sleep Disorders in Adults: Diagnosis and Management. American family physician. Apr 1 2022;105(4):397-405. https://www.ncbi.nlm.nih.gov/pubmed/35426627
- Frase L, Nissen C, Spiegelhalder K, Feige B. The importance and limitations of polysomnography in insomnia disorder-a critical appraisal. J Sleep Res. Dec 2023;32(6):e14036. doi:10.1111/jsr.14036. https://www.ncbi.nlm.nih.gov/pubmed/37680011
- NHLBI. National Heart, Lung, and Blood Institute. Insomnia: Causes and Risk Factors. Available at https://www.nhlbi.nih.gov/health/insomnia/causes Last updated 03/24/2022. Accessed 07/10/2025. 2022;
- Carmona NE, Solomon NL, Adams KE. Sleep disturbance and menopause. Curr Opin Obstet Gynecol. Apr 1 2025;37(2):75-82. doi:10.1097/GCO.0000000000001012. https://www.ncbi.nlm.nih.gov/pubmed/39820156 https://www.ingentaconnect.com/content/wk/coogy/2025/00000037/00000002/art00008
- Pajediene E, Urbonaviciute V, Ramanauskaite V, Strazdauskas L, Stefani A. Sex Differences in Insomnia and Circadian Rhythm Disorders: A Systematic Review. Medicina (Kaunas, Lithuania). Mar 13 2024;60(3)doi:10.3390/medicina60030474. https://www.ncbi.nlm.nih.gov/pubmed/38541200
- Hachul H, Hachul de Campos B, Lucena L, Tufik S. Sleep During Menopause. Sleep medicine clinics. Dec 2023;18(4):423-433. doi:10.1016/j.jsmc.2023.06.004. https://www.ncbi.nlm.nih.gov/pubmed/38501515
- Proserpio P, Marra S, Campana C, et al. Insomnia and menopause: a narrative review on mechanisms and treatments. Climacteric : the journal of the International Menopause Society. Dec 2020;23(6):539-549. doi:10.1080/13697137.2020.1799973. https://www.ncbi.nlm.nih.gov/pubmed/32880197 https://www.tandfonline.com/doi/10.1080/13697137.2020.1799973?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub 0pubmed
- Barrett-Connor E, Dam TT, Stone K, et al. The association of testosterone levels with overall sleep quality, sleep architecture, and sleep-disordered breathing. J Clin Endocrinol Metab. Jul 2008;93(7):2602-9. doi:10.1210/jc.2007-2622. https://www.ncbi.nlm.nih.gov/pubmed/18413429 https://academic.oup.com/jcem/article-abstract/93/7/2602/2598749?redirectedFrom=fulltext
- Kim SD, Cho KS. Obstructive Sleep Apnea and Testosterone Deficiency. World J Mens Health. Jan 2019;37(1):12-18. doi:10.5534/wjmh.180017. https://www.ncbi.nlm.nih.gov/pubmed/29774669
- Wittert G. The relationship between sleep disorders and testosterone in men. Asian journal of andrology. Mar-Apr 2014;16(2):262-5. doi:10.4103/1008-682X.122586. https://www.ncbi.nlm.nih.gov/pubmed/24435056 https://pmc.ncbi.nlm.nih.gov/articles/PMC3955336/
- Burschtin O, Wang J. Testosterone Deficiency and Sleep Apnea. Sleep medicine clinics. Dec 2016;11(4):525-529. doi:10.1016/j.jsmc.2016.08.003. https://www.ncbi.nlm.nih.gov/pubmed/28118875
- Canguven O, Salepci B, Albayrak S, Selimoglu A, Balaban M, Bulbul M. Is there a correlation between testosterone levels and the severity of the disease in male patients with obstructive sleep apnea? Arch Ital Urol Androl. Dec 2010;82(4):143-7. https://www.ncbi.nlm.nih.gov/pubmed/21341549
- Mayo Clinic. Symptoms & causes. Obstructive sleep apnea. Updated 7/14/2023. Accessed 6/26/2025, https://www.mayoclinic.org/diseases-conditions/obstructive-sleep-apnea/symptoms-causes/syc-20352090
- NSF. National Sleep Foundation. Sleep Apnea. Updated 12/26/2024. Accessed 6/26/2025, https://www.sleepfoundation.org/sleep-apnea
- Punjabi NM. The epidemiology of adult obstructive sleep apnea. Proceedings of the American Thoracic Society. Feb 15 2008;5(2):136-43. doi:10.1513/pats.200709-155MG. https://www.ncbi.nlm.nih.gov/pubmed/18250205 https://pmc.ncbi.nlm.nih.gov/articles/PMC2645248/
- Drager LF, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: an emerging risk factor for atherosclerosis. Chest. Aug 2011;140(2):534-542. doi:10.1378/chest.10-2223. https://www.ncbi.nlm.nih.gov/pubmed/21813534 https://pmc.ncbi.nlm.nih.gov/articles/PMC3198492/
- Protasiewicz-Timofticiuc DC, Badescu D, Mota M, et al. Back to Roots: Dysbiosis, Obesity, Metabolic Syndrome, Type 2 Diabetes Mellitus, and Obstructive Sleep Apnea-Is There an Objective Connection? A Narrative Review. Nutrients. Nov 26 2024;16(23)doi:10.3390/nu16234057. https://www.ncbi.nlm.nih.gov/pubmed/39683451
- Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. Jul 27 2010;122(4):352-60. doi:10.1161/CIRCULATIONAHA.109.901801. https://www.ncbi.nlm.nih.gov/pubmed/20625114
- Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. Nov 2011;58(5):811-7. doi:10.1161/HYPERTENSIONAHA.111.179788. https://www.ncbi.nlm.nih.gov/pubmed/21968750
- Aronsohn RS, Whitmore H, Van Cauter E, Tasali E. Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes. American journal of respiratory and critical care medicine. Mar 1 2010;181(5):507-13. doi:10.1164/rccm.200909-1423OC. https://www.ncbi.nlm.nih.gov/pubmed/20019340 https://pmc.ncbi.nlm.nih.gov/articles/PMC2830401/
- Nieto FJ, Peppard PE, Young T, Finn L, Hla KM, Farre R. Sleep-disordered breathing and cancer mortality: results from the Wisconsin Sleep Cohort Study. American journal of respiratory and critical care medicine. Jul 15 2012;186(2):190-4. doi:10.1164/rccm.201201-0130OC. https://www.ncbi.nlm.nih.gov/pubmed/22610391 https://pmc.ncbi.nlm.nih.gov/articles/PMC3406081/
- Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. The New England journal of medicine. Nov 10 2005;353(19):2034-41. doi:10.1056/NEJMoa043104. https://www.ncbi.nlm.nih.gov/pubmed/16282178
- Morin CM, LeBlanc M, Daley M, Gregoire JP, Merette C. Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med. Mar 2006;7(2):123-30. doi:10.1016/j.sleep.2005.08.008. https://www.ncbi.nlm.nih.gov/pubmed/16459140
- Buysse DJ, Germain A. Diagnosis, Epidemiology, and Consequences of Insomnia. Primary Psychiatry. 2005;12(8):37-44.
- Baroni A, Hernandez M, Grant MC, Faedda GL. Sleep Disturbances in Pediatric Bipolar Disorder: A Comparison between Bipolar I and Bipolar NOS. Frontiers in psychiatry. 2012;3:22. doi:10.3389/fpsyt.2012.00022. https://www.ncbi.nlm.nih.gov/pubmed/22454624
- Yokoyama E, Kaneita Y, Saito Y, et al. Association between depression and insomnia subtypes: a longitudinal study on the elderly in Japan. Sleep. Dec 2010;33(12):1693-702. doi:10.1093/sleep/33.12.1693. https://www.ncbi.nlm.nih.gov/pubmed/21120150 https://pmc.ncbi.nlm.nih.gov/articles/PMC2982740/
- Xue Y, Wang WD, Liu YJ, Wang J, Walters AS. Sleep disturbances in generalized anxiety Disorder: The central role of insomnia. Sleep Med. Aug 2025;132:106545. doi:10.1016/j.sleep.2025.106545. https://www.ncbi.nlm.nih.gov/pubmed/40318600 https://www.sciencedirect.com/science/article/abs/pii/S138994572500214X?via%3Dihub
- Hanacek C, Lane J, Tang YL. Insomnia in Patients With Substance Use Disorders: Assessment and Management. J Psychiatr Pract. Jan 1 2025;31(1):2-7. doi:10.1097/PRA.0000000000000832. https://www.ncbi.nlm.nih.gov/pubmed/39836674
- Roane BM, Taylor DJ. Adolescent insomnia as a risk factor for early adult depression and substance abuse. Sleep. Oct 2008;31(10):1351-6. https://www.ncbi.nlm.nih.gov/pubmed/18853932 https://pmc.ncbi.nlm.nih.gov/articles/PMC2572740/
- Singareddy R, Vgontzas AN, Fernandez-Mendoza J, et al. Risk factors for incident chronic insomnia: a general population prospective study. Sleep Med. Apr 2012;13(4):346-53. doi:10.1016/j.sleep.2011.10.033. https://www.ncbi.nlm.nih.gov/pubmed/22425576 https://pmc.ncbi.nlm.nih.gov/articles/PMC3319648/
- Franzen PL, Buysse DJ, Dahl RE, Thompson W, Siegle GJ. Sleep deprivation alters pupillary reactivity to emotional stimuli in healthy young adults. Biol Psychol. Mar 2009;80(3):300-5. doi:10.1016/j.biopsycho.2008.10.010. https://www.ncbi.nlm.nih.gov/pubmed/19041689 https://pmc.ncbi.nlm.nih.gov/articles/PMC3107827/
- Baglioni C, Spiegelhalder K, Regen W, et al. Insomnia disorder is associated with increased amygdala reactivity to insomnia-related stimuli. Sleep. Dec 1 2014;37(12):1907-17. doi:10.5665/sleep.4240. https://www.ncbi.nlm.nih.gov/pubmed/25325493 https://pmc.ncbi.nlm.nih.gov/articles/PMC4548513/
- Bastien CH, St-Jean G, Morin CM, Turcotte I, Carrier J. Chronic psychophysiological insomnia: hyperarousal and/or inhibition deficits? An ERPs investigation. Sleep. Jun 2008;31(6):887-98. doi:10.1093/sleep/31.6.887. https://www.ncbi.nlm.nih.gov/pubmed/18548835 https://pmc.ncbi.nlm.nih.gov/articles/PMC2442415/
- Espie CA. Insomnia: conceptual issues in the development, persistence, and treatment of sleep disorder in adults. Annual review of psychology. 2002;53:215-43. doi:10.1146/annurev.psych.53.100901.135243. https://www.ncbi.nlm.nih.gov/pubmed/11752485 https://www.annualreviews.org/content/journals/10.1146/annurev.psych.53.100901.135243
- van de Laar M, Pevernagie D, van Mierlo P, Overeem S. Psychiatric comorbidity and aspects of cognitive coping negatively predict outcome in cognitive behavioral treatment of psychophysiological insomnia. Behavioral sleep medicine. 2015/03/04 2015;13(2):140-56. doi:10.1080/15402002.2013.845781. https://www.ncbi.nlm.nih.gov/pubmed/24707880
- Green ME, Bernet V, Cheung J. Thyroid Dysfunction and Sleep Disorders. Frontiers in endocrinology. 2021;12:725829. doi:10.3389/fendo.2021.725829. https://www.ncbi.nlm.nih.gov/pubmed/34504473
- Salwen-Deremer JK, Sun M. Management of Sleep and Fatigue in Gastrointestinal Patients. Gastroenterology clinics of North America. Dec 2022;51(4):829-847. doi:10.1016/j.gtc.2022.07.007. https://www.ncbi.nlm.nih.gov/pubmed/36375999 https://www.sciencedirect.com/science/article/abs/pii/S0889855322000450?via%3Dihub
- Xia L, Liu H, Ren J. A review of symptom, pathogenesis and treatment characteristics of the elderly with chronic insomnia. Medicine. Jan 31 2025;104(5):e41346. doi:10.1097/MD.0000000000041346. https://www.ncbi.nlm.nih.gov/pubmed/39889161
- Chang TL, Kuo HC. Nocturia, nocturnal polyuria, and nocturnal enuresis in adults: What we know and what we do not know. Tzu Chi Med J. Oct-Dec 2024;36(4):370-376. doi:10.4103/tcmj.tcmj_53_24. https://www.ncbi.nlm.nih.gov/pubmed/39421492 https://pmc.ncbi.nlm.nih.gov/articles/PMC11483088/
- Pesonen JS, Cartwright R, Vernooij RWM, et al. The Impact of Nocturia on Mortality: A Systematic Review and Meta-Analysis. J Urol. Mar 2020;203(3):486-495. doi:10.1097/JU.0000000000000463. https://www.ncbi.nlm.nih.gov/pubmed/31364920
- Weiss JP, Everaert K. Management of Nocturia and Nocturnal Polyuria. Urology. Nov 2019;133S:24-33. doi:10.1016/j.urology.2019.09.022. https://www.ncbi.nlm.nih.gov/pubmed/31586470
- Pauwaert K, Goessaert AS, Robinson D, et al. Nocturia in Menopausal Women: The Link Between Two Common Problems of the Middle Age. Int Urogynecol J. May 2024;35(5):935-946. doi:10.1007/s00192-024-05743-1. https://www.ncbi.nlm.nih.gov/pubmed/38436669 https://link.springer.com/article/10.1007/s00192-024-05743-1
- Song QX, Suadicani SO, Negoro H, et al. Disruption of circadian rhythm as a potential pathogenesis of nocturia. Nature reviews Urology. May 2025;22(5):276-293. doi:10.1038/s41585-024-00961-0. https://www.ncbi.nlm.nih.gov/pubmed/39543359 https://pmc.ncbi.nlm.nih.gov/articles/PMC12285584/
- Monaghan TF, Weiss JP, Wein AJ, et al. Sleep Disorders, Comorbidities, Actions, Lower Urinary Tract Dysfunction, and Medications ("Sleep C.A.L.M.") in the evaluation and management of nocturia: A simple approach to a complex diagnosis. Neurourology and urodynamics. Mar 2023;42(3):562-572. doi:10.1002/nau.25128. https://www.ncbi.nlm.nih.gov/pubmed/36655726
- Verbakel I, Boukheir G, Bliwise D, et al. From nocturnal awakenings to nocturnal voiding: the relationship between insomnia and nocturia - a systematic review. Minerva Urol Nephrol. Apr 2025;77(2):181-191. doi:10.23736/S2724-6051.23.05384-3. https://www.ncbi.nlm.nih.gov/pubmed/37955855
- NSF. National Sleep Foundation. What causes insomnia? Updated 1/16/2024. Accessed 6/26/2025, https://www.sleepfoundation.org/insomnia/what-causes-insomnia
- Dhaval Patel MJS, MD; Pragnesh Patel, MD. Insomnia in the Elderly: A Review. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2018;14(6):1017-1024. http://jcsm.aasm.org/ViewAbstract.aspx?pid=31287
- Carroll JE, Irwin MR, Levine M, et al. Epigenetic Aging and Immune Senescence in Women With Insomnia Symptoms: Findings From the Women's Health Initiative Study. Biological psychiatry. Jan 15 2017;81(2):136-144. doi:10.1016/j.biopsych.2016.07.008. https://www.ncbi.nlm.nih.gov/pubmed/27702440
- Do D. Trends in the use of medications with insomnia side effects and the implications for insomnia among US adults. J Sleep Res. Aug 2020;29(4):e13075. doi:10.1111/jsr.13075. https://www.ncbi.nlm.nih.gov/pubmed/32410359
- Van Gastel A. Drug-Induced Insomnia and Excessive Sleepiness. Sleep medicine clinics. Sep 2022;17(3):471-484. doi:10.1016/j.jsmc.2022.06.011. https://www.ncbi.nlm.nih.gov/pubmed/36150808
- Neikrug AB, Ancoli-Israel S. Sleep disorders in the older adult - a mini-review. Gerontology. 2010;56(2):181-9. doi:10.1159/000236900. https://www.ncbi.nlm.nih.gov/pubmed/19738366 https://pmc.ncbi.nlm.nih.gov/articles/PMC2842167/
- Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol. Mar 2010;49(3):239-48. doi:10.1111/j.1365-4632.2009.04322.x. https://www.ncbi.nlm.nih.gov/pubmed/20465658
- Nerbass FB, Pedrosa RP, Genta PR, Drager LF, Lorenzi-Filho G. Calcium channel blockers are independently associated with short sleep duration in hypertensive patients with obstructive sleep apnea. Journal of hypertension. Jun 2011;29(6):1236-41. doi:10.1097/HJH.0b013e3283462e8b. https://www.ncbi.nlm.nih.gov/pubmed/21546880
- Bercovitch RS, Tsai SC. Respiratory medications and sleep. journal article. Current Respiratory Care Reports. June 01 2012;1(2):123-130. doi:10.1007/s13665-012-0013-1. https://doi.org/10.1007/s13665-012-0013-1 https://link.springer.com/content/pdf/10.1007/s13665-012-0013-1.pdf
- Gurley BJ, Steelman SC, Thomas SL. Multi-ingredient, caffeine-containing dietary supplements: history, safety, and efficacy. Clin Ther. Feb 1 2015;37(2):275-301. doi:10.1016/j.clinthera.2014.08.012. https://www.ncbi.nlm.nih.gov/pubmed/25262198
- Roehrs T, Roth T. Caffeine: sleep and daytime sleepiness. Sleep medicine reviews. Apr 2008;12(2):153-62. doi:10.1016/j.smrv.2007.07.004. https://www.ncbi.nlm.nih.gov/pubmed/17950009
- Chaudhary NS, Grandner MA, Jackson NJ, Chakravorty S. Caffeine consumption, insomnia, and sleep duration: Results from a nationally representative sample. Nutrition (Burbank, Los Angeles County, Calif). Nov-Dec 2016;32(11-12):1193-9. doi:10.1016/j.nut.2016.04.005. https://www.ncbi.nlm.nih.gov/pubmed/27377580 https://pmc.ncbi.nlm.nih.gov/articles/PMC6230475/
- Clark I, Landolt HP. Coffee, caffeine, and sleep: A systematic review of epidemiological studies and randomized controlled trials. Sleep medicine reviews. Feb 2017;31:70-78. doi:10.1016/j.smrv.2016.01.006. https://www.ncbi.nlm.nih.gov/pubmed/26899133
- Youngberg MR, Karpov IO, Begley A, Pollock BG, Buysse DJ. Clinical and physiological correlates of caffeine and caffeine metabolites in primary insomnia. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. Apr 15 2011;7(2):196-203. https://www.ncbi.nlm.nih.gov/pubmed/21509336 https://pmc.ncbi.nlm.nih.gov/articles/PMC3077349/
- Jaehne A, Loessl B, Barkai Z, Riemann D, Hornyak M. Effects of nicotine on sleep during consumption, withdrawal and replacement therapy. Sleep medicine reviews. Oct 2009;13(5):363-77. doi:10.1016/j.smrv.2008.12.003. https://www.ncbi.nlm.nih.gov/pubmed/19345124
- Brook JS, Zhang C, Rubenstone E, Brook DW. Insomnia in adults: the impact of earlier cigarette smoking from adolescence to adulthood. Journal of addiction medicine. Jan-Feb 2015;9(1):40-5. doi:10.1097/ADM.0000000000000083. https://www.ncbi.nlm.nih.gov/pubmed/25325299 https://pmc.ncbi.nlm.nih.gov/articles/PMC4310766/
- Sabanayagam C, Shankar A. The association between active smoking, smokeless tobacco, second-hand smoke exposure and insufficient sleep. Sleep Med. Jan 2011;12(1):7-11. doi:10.1016/j.sleep.2010.09.002. https://www.ncbi.nlm.nih.gov/pubmed/21144798 https://pmc.ncbi.nlm.nih.gov/articles/PMC3056485/
- Hendler RA, Ramchandani VA, Gilman J, Hommer DW. Stimulant and sedative effects of alcohol. Curr Top Behav Neurosci. 2013;13:489-509. doi:10.1007/7854_2011_135. https://www.ncbi.nlm.nih.gov/pubmed/21560041 https://link.springer.com/chapter/10.1007/978-3-642-28720-6_135
- Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res. Aug 2008;32(8):1429-38. doi:10.1111/j.1530-0277.2008.00706.x. https://www.ncbi.nlm.nih.gov/pubmed/18540923
- Stein MD, Friedmann PD. Disturbed sleep and its relationship to alcohol use. Subst Abus. Mar 2005;26(1):1-13. doi:10.1300/j465v26n01_01. https://www.ncbi.nlm.nih.gov/pubmed/16492658 https://pmc.ncbi.nlm.nih.gov/articles/PMC2775419/
- Brooks AT, Wallen GR. Sleep Disturbances in Individuals with Alcohol-Related Disorders: A Review of Cognitive-Behavioral Therapy for Insomnia (CBT-I) and Associated Non-Pharmacological Therapies. Subst Abuse. 2014/01/01 2014;8:55-62. doi:10.4137/SART.S18446. https://www.ncbi.nlm.nih.gov/pubmed/25288884 https://pmc.ncbi.nlm.nih.gov/articles/PMC4179428/
- Zhabenko N, Wojnar M, Brower KJ. Prevalence and correlates of insomnia in a polish sample of alcohol-dependent patients. Alcohol Clin Exp Res. Sep 2012;36(9):1600-7. doi:10.1111/j.1530-0277.2012.01771.x. https://www.ncbi.nlm.nih.gov/pubmed/22471339 https://deepblue.lib.umich.edu/bitstream/handle/2027.42/93735/acer1771.pdf?sequence=1
- Brower KJ, Krentzman A, Robinson EA. Persistent insomnia, abstinence, and moderate drinking in alcohol-dependent individuals. Am J Addict. Sep-Oct 2011;20(5):435-40. doi:10.1111/j.1521-0391.2011.00152.x. https://www.ncbi.nlm.nih.gov/pubmed/21838842
- Baglioni C, Spiegelhalder K, Lombardo C, Riemann D. Sleep and emotions: a focus on insomnia. Sleep medicine reviews. Aug 2010;14(4):227-38. doi:10.1016/j.smrv.2009.10.007. https://www.ncbi.nlm.nih.gov/pubmed/20137989 https://www.sciencedirect.com/science/article/abs/pii/S1087079209001178?via%3Dihub
- Fernandez-Mendoza J, Vela-Bueno A, Vgontzas AN, et al. Cognitive-emotional hyperarousal as a premorbid characteristic of individuals vulnerable to insomnia. Psychosomatic medicine. May 2010;72(4):397-403. doi:10.1097/PSY.0b013e3181d75319. https://www.ncbi.nlm.nih.gov/pubmed/20368477
- Mayo Clinic. Insomnia. Symptoms & causes. https://www.mayoclinic.org/diseases-conditions/insomnia/symptoms-causes/syc-20355167. 10/15/2016. Accessed 4/2/2019.
- Kolla BP, Auger RR. Jet lag and shift work sleep disorders: how to help reset the internal clock. Cleveland Clinic journal of medicine. Oct 2011;78(10):675-84. doi:10.3949/ccjm.78a.10083. https://www.ncbi.nlm.nih.gov/pubmed/21968474
- NSF. National Sleep Foundation. Shift Work Disorder. Updated 11/3/2023. Accessed 6/26/2025, https://www.sleepfoundation.org/shift-work-disorder
- Mayo Clinic. Insomnia. Updated 1/16/2024. Accessed 6/26/2025, https://www.mayoclinic.org/diseases-conditions/insomnia/symptoms-causes/syc-20355167
- Bertisch SM, Pollock BD, Mittleman MA, et al. Insomnia with objective short sleep duration and risk of incident cardiovascular disease and all-cause mortality: Sleep Heart Health Study. Sleep. Jun 1 2018;41(6)doi:10.1093/sleep/zsy047. https://www.ncbi.nlm.nih.gov/pubmed/29522193 https://pmc.ncbi.nlm.nih.gov/articles/PMC5995202/
- Vatten LJ, Strand LB, Laugsand LE, Platou C, Janszky I. Insomnia and the risk of incident heart failure: a population study. European Heart Journal. 2013;35(21):1382-1393. doi:10.1093/eurheartj/eht019 %J European Heart Journal. https://dx.doi.org/10.1093/eurheartj/eht019
- Dominguez F, Fuster V, Fernandez-Alvira JM, et al. Association of Sleep Duration and Quality With Subclinical Atherosclerosis. Journal of the American College of Cardiology. Jan 22 2019;73(2):134-144. doi:10.1016/j.jacc.2018.10.060. https://www.ncbi.nlm.nih.gov/pubmed/30654884
- Ibarra-Coronado EG, Pantaleon-Martinez AM, Velazquez-Moctezuma J, et al. The Bidirectional Relationship between Sleep and Immunity against Infections. J Immunol Res. 2015;2015:678164. 678164. doi:10.1155/2015/678164. https://www.ncbi.nlm.nih.gov/pubmed/26417606
- Irwin MR, Olmstead R, Carroll JE. Sleep Disturbance, Sleep Duration, and Inflammation: A Systematic Review and Meta-Analysis of Cohort Studies and Experimental Sleep Deprivation. Biological psychiatry. Jul 1 2016;80(1):40-52. doi:10.1016/j.biopsych.2015.05.014. https://www.ncbi.nlm.nih.gov/pubmed/26140821
- Aldabal L, Bahammam AS. Metabolic, endocrine, and immune consequences of sleep deprivation. Open Respir Med J. 2011;5:31-43. doi:10.2174/1874306401105010031. https://www.ncbi.nlm.nih.gov/pubmed/21754974 https://pmc.ncbi.nlm.nih.gov/articles/PMC3132857/
- Bonnet MH, Arand DL. Hyperarousal and insomnia: state of the science. Sleep medicine reviews. Feb 2010;14(1):9-15. doi:10.1016/j.smrv.2009.05.002. https://www.ncbi.nlm.nih.gov/pubmed/19640748 https://www.sciencedirect.com/science/article/abs/pii/S1087079209000458?via%3Dihub
- Zhang J, Ma RC, Kong AP, et al. Relationship of sleep quantity and quality with 24-hour urinary catecholamines and salivary awakening cortisol in healthy middle-aged adults. Sleep. Feb 1 2011;34(2):225-33. doi:10.1093/sleep/34.2.225. https://www.ncbi.nlm.nih.gov/pubmed/21286244 https://pmc.ncbi.nlm.nih.gov/articles/PMC3022944/
- Dressle RJ, Feige B, Spiegelhalder K, et al. HPA axis activity in patients with chronic insomnia: A systematic review and meta-analysis of case-control studies. Sleep medicine reviews. Apr 2022;62:101588. doi:10.1016/j.smrv.2022.101588. https://www.ncbi.nlm.nih.gov/pubmed/35091194 https://www.sciencedirect.com/science/article/abs/pii/S1087079222000016?via%3Dihub
- Figorilli M, Velluzzi F, Redolfi S. Obesity and sleep disorders: A bidirectional relationship. Nutr Metab Cardiovasc Dis. Jun 2025;35(6):104014. doi:10.1016/j.numecd.2025.104014. https://www.ncbi.nlm.nih.gov/pubmed/40180826
- Chen Y, Tong E, Rao Y, Yu EY, Zeegers M, Wesselius A. The association between insomnia (related symptoms) and glycaemic control: a systematic review and meta-analysis. J Glob Health. Feb 7 2025;15:04016. doi:10.7189/jogh.15.04016. https://www.ncbi.nlm.nih.gov/pubmed/39916567 https://pmc.ncbi.nlm.nih.gov/articles/PMC11803432/
- Haack M, Scott-Sutherland J, Santangelo G, Simpson NS, Sethna N, Mullington JM. Pain sensitivity and modulation in primary insomnia. Eur J Pain. Apr 2012;16(4):522-33. doi:10.1016/j.ejpain.2011.07.007. https://www.ncbi.nlm.nih.gov/pubmed/22396081
- Schuh-Hofer S, Wodarski R, Pfau DB, et al. One night of total sleep deprivation promotes a state of generalized hyperalgesia: a surrogate pain model to study the relationship of insomnia and pain. Pain. Sep 2013;154(9):1613-1621. doi:10.1016/j.pain.2013.04.046. https://www.ncbi.nlm.nih.gov/pubmed/23707287
- Sung PS, Yeh CC, Wang LC, et al. Increased Risk of Dementia in Patients with Non-Apnea Sleep Disorder. Current Alzheimer research. 2017;14(3):309-316. doi:10.2174/1567205013666161108104703. https://www.ncbi.nlm.nih.gov/pubmed/27829341 https://www.eurekaselect.com/article/79575
- Wong R, Lovier MA. Sleep Disturbances and Dementia Risk in Older Adults: Findings From 10 Years of National U.S. Prospective Data. Am J Prev Med. Jun 2023;64(6):781-787. doi:10.1016/j.amepre.2023.01.008. https://www.ncbi.nlm.nih.gov/pubmed/36707315
- Harsora P, Kessmann J. Nonpharmacologic management of chronic insomnia. American family physician. Jan 15 2009;79(2):125-30. https://www.ncbi.nlm.nih.gov/pubmed/19178064
- Baranwal N, Yu PK, Siegel NS. Sleep physiology, pathophysiology, and sleep hygiene. Progress in cardiovascular diseases. Mar-Apr 2023;77:59-69. doi:10.1016/j.pcad.2023.02.005. https://www.ncbi.nlm.nih.gov/pubmed/36841492 https://www.sciencedirect.com/science/article/abs/pii/S0033062023000117?via%3Dihub
- Chung KF, Lee CT, Yeung WF, Chan MS, Chung EW, Lin WL. Sleep hygiene education as a treatment of insomnia: a systematic review and meta-analysis. Family practice. Jul 23 2018;35(4):365-375. doi:10.1093/fampra/cmx122. https://www.ncbi.nlm.nih.gov/pubmed/29194467
- Gellis LA, Park A, Stotsky MT, Taylor DJ. Associations between sleep hygiene and insomnia severity in college students: cross-sectional and prospective analyses. Behav Ther. Nov 2014;45(6):806-16. doi:10.1016/j.beth.2014.05.002. https://www.ncbi.nlm.nih.gov/pubmed/25311289 https://www.sciencedirect.com/science/article/abs/pii/S0005789414000756?via%3Dihub
- Holt B, Tran S, Cochran A, Saffle J, Lin H, Faraklas I. Impact of a Nursing-Driven Sleep Hygiene Protocol on Sleep Quality. Journal of Burn Care & Research. 2013;34(2):249-254. doi:10.1097/BCR.0b013e318283d175 %J Journal of Burn Care & Research. https://dx.doi.org/10.1097/BCR.0b013e318283d175
- Shin JC, Parab KV, An R, Grigsby-Toussaint DS. Greenspace exposure and sleep: A systematic review. Environ Res. Mar 2020;182:109081. doi:10.1016/j.envres.2019.109081. https://www.ncbi.nlm.nih.gov/pubmed/31891829 https://www.sciencedirect.com/science/article/abs/pii/S0013935119308771?via%3Dihub
- Chen TL, Chang SC, Hsieh HF, Huang CY, Chuang JH, Wang HH. Effects of mindfulness-based stress reduction on sleep quality and mental health for insomnia patients: A meta-analysis. Journal of psychosomatic research. Aug 2020;135:110144. doi:10.1016/j.jpsychores.2020.110144. https://www.ncbi.nlm.nih.gov/pubmed/32590218 https://www.sciencedirect.com/science/article/abs/pii/S0022399920301744?via%3Dihub
- McCurry SM, Logsdon RG, Teri L, Vitiello MV. Sleep disturbances in caregivers of persons with dementia: contributing factors and treatment implications. Sleep medicine reviews. Apr 2007;11(2):143-53. doi:10.1016/j.smrv.2006.09.002. https://www.ncbi.nlm.nih.gov/pubmed/17287134 https://pmc.ncbi.nlm.nih.gov/articles/PMC1861844/
- Hoch CC, Reynolds CF, 3rd, Buysse DJ, et al. Protecting sleep quality in later life: a pilot study of bed restriction and sleep hygiene. The journals of gerontology Series B, Psychological sciences and social sciences. Jan 2001;56(1):P52-9. doi:10.1093/geronb/56.1.p52. https://www.ncbi.nlm.nih.gov/pubmed/11192338
- Miller CB, Espie CA, Epstein DR, et al. The evidence base of sleep restriction therapy for treating insomnia disorder. Sleep medicine reviews. Oct 2014;18(5):415-24. doi:10.1016/j.smrv.2014.01.006. https://www.ncbi.nlm.nih.gov/pubmed/24629826
- Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. Feb 15 2017;13(2):307-349. doi:10.5664/jcsm.6470. https://www.ncbi.nlm.nih.gov/pubmed/27998379
- Lake RC, Tucker RE, Murphy AL, Pencer A, Kruglova K, Gardner DM. A scoping review of self-help cognitive behavioural therapy for insomnia. Sleep medicine reviews. Feb 2025;79:102021. doi:10.1016/j.smrv.2024.102021. https://www.ncbi.nlm.nih.gov/pubmed/39561429
- Edinger JD, Arnedt JT, Bertisch SM, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. Feb 1 2021;17(2):263-298. doi:10.5664/jcsm.8988. https://www.ncbi.nlm.nih.gov/pubmed/33164741
- Edinger JD, Wohlgemuth WK, Radtke RA, Marsh GR, Quillian RE. Cognitive behavioral therapy for treatment of chronic primary insomnia: a randomized controlled trial. JAMA. Apr 11 2001;285(14):1856-64. doi:10.1001/jama.285.14.1856. https://www.ncbi.nlm.nih.gov/pubmed/11308399
- Smith MT, Huang MI, Manber R. Cognitive behavior therapy for chronic insomnia occurring within the context of medical and psychiatric disorders. Clin Psychol Rev. Jul 2005;25(5):559-92. doi:10.1016/j.cpr.2005.04.004. https://www.ncbi.nlm.nih.gov/pubmed/15970367 https://www.sciencedirect.com/science/article/abs/pii/S0272735805000309?via%3Dihub
- Smith MT, Neubauer DN. Cognitive behavior therapy for chronic insomnia. Clinical cornerstone. 2003;5(3):28-40. doi:10.1016/s1098-3597(03)90033-0. https://www.ncbi.nlm.nih.gov/pubmed/14626539 https://www.sciencedirect.com/science/article/abs/pii/S1098359703900330?via%3Dihub
- Savard J, Simard S, Ivers H, Morin CM. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: Sleep and psychological effects. J Clin Oncol. Sep 1 2005;23(25):6083-96. doi:10.1200/JCO.2005.09.548. https://www.ncbi.nlm.nih.gov/pubmed/16135475
- Lancee J, Eisma MC, van Straten A, Kamphuis JH. Sleep-Related Safety Behaviors and Dysfunctional Beliefs Mediate the Efficacy of Online CBT for Insomnia: A Randomized Controlled Trial. Cognitive behaviour therapy. 2015/09/03 2015;44(5):406-22. doi:10.1080/16506073.2015.1026386. https://www.ncbi.nlm.nih.gov/pubmed/26012890
- Mitchell MD, Gehrman P, Perlis M, Umscheid CA. Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. BMC Fam Pract. May 25 2012;13(1):40. doi:10.1186/1471-2296-13-40. https://www.ncbi.nlm.nih.gov/pubmed/22631616
- Brasure M, MacDonald R, Fuchs E, et al. AHRQ Comparative Effectiveness Reviews. Management of Insomnia Disorder. Agency for Healthcare Research and Quality (US); 2015. AHRQ Comparative Effectiveness Reviews.
- Ong JC, Ulmer CS, Manber R. Improving sleep with mindfulness and acceptance: a metacognitive model of insomnia. Behav Res Ther. Nov 2012;50(11):651-60. doi:10.1016/j.brat.2012.08.001. https://www.ncbi.nlm.nih.gov/pubmed/22975073 https://pmc.ncbi.nlm.nih.gov/articles/PMC3466342/
- Gross CR, Kreitzer MJ, Reilly-Spong M, et al. Mindfulness-based stress reduction versus pharmacotherapy for chronic primary insomnia: a randomized controlled clinical trial. Explore (New York, NY). Mar-Apr 2011;7(2):76-87. doi:10.1016/j.explore.2010.12.003. https://www.ncbi.nlm.nih.gov/pubmed/21397868 https://pmc.ncbi.nlm.nih.gov/articles/PMC3077056/
- Afonso RF, Hachul H, Kozasa EH, et al. Yoga decreases insomnia in postmenopausal women: a randomized clinical trial. Menopause (New York, NY). Feb 2012;19(2):186-93. doi:10.1097/gme.0b013e318228225f. https://www.ncbi.nlm.nih.gov/pubmed/22048261
- Salame A, Mathew S, Bhanu C, et al. Over-the-counter products for insomnia in adults: A scoping review of randomised controlled trials. Sleep Med. May 2025;129:219-237. doi:10.1016/j.sleep.2025.02.027. https://www.ncbi.nlm.nih.gov/pubmed/40054227
- Panula P. Histamine receptors, agonists, and antagonists in health and disease. Handbook of clinical neurology. 2021;180:377-387. doi:10.1016/B978-0-12-820107-7.00023-9. https://www.ncbi.nlm.nih.gov/pubmed/34225942
- Randall S, Roehrs TA, Roth T. Over-the-counter sleep aid medications and insomnia. Primary Psychiatry. 2008;15(5):52.
- Leon-Barriera R, Chaplin MM, Kaur J, Modesto-Lowe V. Insomnia in older adults: A review of treatment options. Cleveland Clinic journal of medicine. Jan 2 2025;92(1):43-50. doi:10.3949/ccjm.92a.24073. https://www.ncbi.nlm.nih.gov/pubmed/39746731
- Stone JA, Lester CA, Aboneh EA, Phelan CH, Welch LL, Chui MA. A preliminary examination of over-the-counter medication misuse rates in older adults. Res Social Adm Pharm. Jan-Feb 2017;13(1):187-192. doi:10.1016/j.sapharm.2016.01.004. https://www.ncbi.nlm.nih.gov/pubmed/26853833 https://pmc.ncbi.nlm.nih.gov/articles/PMC4949161/
- Abraham O, Schleiden L, Albert SM. Over-the-counter medications containing diphenhydramine and doxylamine used by older adults to improve sleep. journal article. Int J Clin Pharm. Aug 2017;39(4):808-817. doi:10.1007/s11096-017-0467-x. https://www.ncbi.nlm.nih.gov/pubmed/28466395
- Albert SM, Roth T, Toscani M, Vitiello MV, Zee P. Sleep Health and Appropriate Use of OTC Sleep Aids in Older Adults-Recommendations of a Gerontological Society of America Workgroup. The Gerontologist. Apr 1 2017;57(2):163-170. doi:10.1093/geront/gnv139. https://www.ncbi.nlm.nih.gov/pubmed/26511271
- Lieberman JA. Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care. Primary care companion to the Journal of clinical psychiatry. 2007;9(1):25-31. doi:10.4088/pcc.v09n0105. https://www.ncbi.nlm.nih.gov/pubmed/17599165 https://pmc.ncbi.nlm.nih.gov/articles/PMC1894851/
- Bourgeois J, Elseviers MM, Van Bortel L, Petrovic M, Vander Stichele RH. One-year evolution of sleep quality in older users of benzodiazepines: a longitudinal cohort study in belgian nursing home residents. Drugs Aging. Sep 2014;31(9):677-82. doi:10.1007/s40266-014-0203-3. https://www.ncbi.nlm.nih.gov/pubmed/25145751 https://link.springer.com/article/10.1007/s40266-014-0203-3
- Greenblatt DJ, Roth T. Zolpidem for insomnia. Expert opinion on pharmacotherapy. Apr 2012;13(6):879-93. doi:10.1517/14656566.2012.667074. https://www.ncbi.nlm.nih.gov/pubmed/22424586
- Roth T, Walsh JK, Krystal A, Wessel T, Roehrs TA. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med. Nov 2005;6(6):487-95. doi:10.1016/j.sleep.2005.06.004. https://www.ncbi.nlm.nih.gov/pubmed/16230048 https://www.sciencedirect.com/science/article/abs/pii/S1389945705001371?via%3Dihub
- Ancoli-Israel S, Krystal AD, McCall WV, et al. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep. Feb 2010;33(2):225-34. doi:10.1093/sleep/33.2.225. https://www.ncbi.nlm.nih.gov/pubmed/20175406 https://pmc.ncbi.nlm.nih.gov/articles/PMC2817909/
- FDA. U.S. Food & Drug Administration. FDA Drug Safety Communication: FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose. Updated 1/15/2016. Accessed 6/26/2025, https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-next-day-impairment-sleep-aid-lunesta-eszopiclone-and-lowers
- Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN. Adverse Effects of Hypnotic Medications. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. Jun 15 2017;13(6):839. doi:10.5664/jcsm.6634. https://www.ncbi.nlm.nih.gov/pubmed/28454603 https://pmc.ncbi.nlm.nih.gov/articles/PMC5443747/
- Harbourt K, Nevo ON, Zhang R, Chan V, Croteau D. Association of eszopiclone, zaleplon, or zolpidem with complex sleep behaviors resulting in serious injuries, including death. Pharmacoepidemiology and drug safety. Jun 2020;29(6):684-691. doi:10.1002/pds.5004. https://www.ncbi.nlm.nih.gov/pubmed/32323442
- Wichniak A, Wierzbicka A, Walecka M, Jernajczyk W. Effects of Antidepressants on Sleep. journal article. Curr Psychiatry Rep. Aug 9 2017;19(9):63. doi:10.1007/s11920-017-0816-4. https://www.ncbi.nlm.nih.gov/pubmed/28791566
- Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep. Nov 2007;30(11):1555-61. doi:10.1093/sleep/30.11.1555. https://www.ncbi.nlm.nih.gov/pubmed/18041488 https://pmc.ncbi.nlm.nih.gov/articles/PMC2082089/
- Krystal AD, Durrence HH, Scharf M, et al. Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia. Sleep. Nov 2010;33(11):1553-61. doi:10.1093/sleep/33.11.1553. https://www.ncbi.nlm.nih.gov/pubmed/21102997 https://pmc.ncbi.nlm.nih.gov/articles/PMC2954705/
- Krystal AD, Lankford A, Durrence HH, et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep. Oct 1 2011;34(10):1433-42. doi:10.5665/SLEEP.1294. https://www.ncbi.nlm.nih.gov/pubmed/21966075 https://pmc.ncbi.nlm.nih.gov/articles/PMC3174845/
- Walsh JK, Erman M, Erwin C, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII–R primary insomnia. Human Psychopharmacology: Clinical and Experimental. 1998;13(3):191-198.
- Nazarian PK, Park SH. Antidepressant management of insomnia disorder in the absence of a mood disorder. Mental Health Clinician. 2014;4:41-46. https://mhc.cpnp.org/doi/full/10.9740/mhc.n188364
- Roth AJ, McCall WV, Liguori A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. J Sleep Res. Dec 2011;20(4):552-8. doi:10.1111/j.1365-2869.2011.00928.x. https://www.ncbi.nlm.nih.gov/pubmed/21623982 https://pmc.ncbi.nlm.nih.gov/articles/PMC3165092/
- Camargos EF, Louzada LL, Quintas JL, Naves JO, Louzada FM, Nobrega OT. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. Am J Geriatr Psychiatry. Dec 2014;22(12):1565-74. doi:10.1016/j.jagp.2013.12.174. https://www.ncbi.nlm.nih.gov/pubmed/24495406
- Anderson SL, Vande Griend JP. Quetiapine for insomnia: A review of the literature. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. Mar 1 2014;71(5):394-402. doi:10.2146/ajhp130221. https://www.ncbi.nlm.nih.gov/pubmed/24534594
- Modesto-Lowe V, Harabasz AK, Walker SA. Quetiapine for primary insomnia: Consider the risks. Cleveland Clinic journal of medicine. May 3 2021;88(5):286-294. doi:10.3949/ccjm.88a.20031. https://www.ncbi.nlm.nih.gov/pubmed/33941603
- Mogavero MP, Silvani A, Lanza G, DelRosso LM, Ferini-Strambi L, Ferri R. Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations. Nature and science of sleep. 2023;15:17-38. doi:10.2147/NSS.S201994. https://www.ncbi.nlm.nih.gov/pubmed/36713640
- Jacobson LH, Hoyer D, de Lecea L. Hypocretins (orexins): The ultimate translational neuropeptides. J Intern Med. May 2022;291(5):533-556. doi:10.1111/joim.13406. https://www.ncbi.nlm.nih.gov/pubmed/35043499
- Palagini L, Geoffroy PA, Balestrieri M, et al. Current models of insomnia disorder: a theoretical review on the potential role of the orexinergic pathway with implications for insomnia treatment. J Sleep Res. Aug 2023;32(4):e13825. doi:10.1111/jsr.13825. https://www.ncbi.nlm.nih.gov/pubmed/36786121
- Clark JW, Brian ML, Drummond SPA, Hoyer D, Jacobson LH. Effects of orexin receptor antagonism on human sleep architecture: A systematic review. Sleep medicine reviews. Oct 2020;53:101332. doi:10.1016/j.smrv.2020.101332. https://www.ncbi.nlm.nih.gov/pubmed/32505969 https://www.sciencedirect.com/science/article/abs/pii/S1087079220300757?via%3Dihub
- Carpi M, Palagini L, Fernandes M, et al. Clinical usefulness of dual orexin receptor antagonism beyond insomnia: Neurological and psychiatric comorbidities. Neuropharmacology. Mar 1 2024;245:109815. doi:10.1016/j.neuropharm.2023.109815. https://www.ncbi.nlm.nih.gov/pubmed/38114045 https://www.sciencedirect.com/science/article/pii/S0028390823004057?via%3Dihub
- Panda SP, Sinha S, Kesharwani A, et al. Role of OX/OXR cascade in insomnia and sleep deprivation link Alzheimer's disease and Parkinson's disease: Therapeutic avenue of Dual OXR Antagonist (DORA). Biochemical pharmacology. Mar 2025;233:116794. doi:10.1016/j.bcp.2025.116794. https://www.ncbi.nlm.nih.gov/pubmed/39920976
- Kishi T, Koebis M, Sugawara M, Kawatsu Y, Taninaga T, Iwata N. Orexin receptor antagonists in the treatment of insomnia associated with psychiatric disorders: a systematic review. Translational psychiatry. Sep 14 2024;14(1):374. doi:10.1038/s41398-024-03087-4. https://www.ncbi.nlm.nih.gov/pubmed/39277609
- Coleman PJ, Gotter AL, Herring WJ, Winrow CJ, Renger JJ. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia. Annual review of pharmacology and toxicology. Jan 6 2017;57:509-533. doi:10.1146/annurev-pharmtox-010716-104837. https://www.ncbi.nlm.nih.gov/pubmed/27860547
- Kishi T, Ikuta T, Citrome L, et al. Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis. Translational psychiatry. Jun 24 2025;15(1):211. doi:10.1038/s41398-025-03439-8. https://www.ncbi.nlm.nih.gov/pubmed/40555730
- Na HJ, Jeon N, Staatz CE, Han N, Baek IH. Clinical safety and narcolepsy-like symptoms of dual orexin receptor antagonists in patients with insomnia: a systematic review and meta-analysis. Sleep. Feb 8 2024;47(2)doi:10.1093/sleep/zsad293. https://www.ncbi.nlm.nih.gov/pubmed/37950346
- Rocha RB, Bomtempo FF, Nager GB, Cenci GI, Telles JPM. Dual orexin receptor antagonists for the treatment of insomnia: systematic review and network meta-analysis. Arquivos de neuro-psiquiatria. May 2023;81(5):475-483. Antagonistas duais do receptor de orexina para o tratamento da insonia: revisao sistematica e metanalise em rede. doi:10.1055/s-0043-1768667. https://www.ncbi.nlm.nih.gov/pubmed/37257468
- Xue T, Wu X, Chen S, et al. The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis. Sleep medicine reviews. Feb 2022;61:101573. doi:10.1016/j.smrv.2021.101573. https://www.ncbi.nlm.nih.gov/pubmed/34902823 https://www.sciencedirect.com/science/article/abs/pii/S1087079221001581?via%3Dihub
- Kripke DF, Garfinkel L, Wingard DL, Klauber MR, Marler MR. Mortality associated with sleep duration and insomnia. Archives of general psychiatry. Feb 2002;59(2):131-6. doi:10.1001/archpsyc.59.2.131. https://www.ncbi.nlm.nih.gov/pubmed/11825133 https://jamanetwork.com/journals/jamapsychiatry/fullarticle/206050
- Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annual review of pharmacology and toxicology. 2016;56:361-83. doi:10.1146/annurev-pharmtox-010814-124742. https://www.ncbi.nlm.nih.gov/pubmed/26514204
- Miyamoto M. [A novel therapeutic drug: ramelteon]. Nihon rinsho Japanese journal of clinical medicine. Aug 2009;67(8):1595-600. https://www.ncbi.nlm.nih.gov/pubmed/19768947
- Praveena Devi C, Samreen S, Kumari NK, Sharma JVC. A review on insomnia: The sleep disorder. 2018;7(12):227-230. https://www.thepharmajournal.com/archives/2018/vol7issue12/PartE/7-11-125-807.pdf
- Turek FW, Gillette MU. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med. Nov 2004;5(6):523-32. doi:10.1016/j.sleep.2004.07.009. https://www.ncbi.nlm.nih.gov/pubmed/15511698 https://www.sciencedirect.com/science/article/abs/pii/S1389945704001315?via%3Dihub
- Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. Feb 2005;48(2):301-10. doi:10.1016/j.neuropharm.2004.09.007. https://www.ncbi.nlm.nih.gov/pubmed/15695169
- Sateia MJ, Kirby-Long P, Taylor JL. Efficacy and clinical safety of ramelteon: an evidence-based review. Sleep medicine reviews. Aug 2008;12(4):319-32. doi:10.1016/j.smrv.2007.12.005. https://www.ncbi.nlm.nih.gov/pubmed/18603221 https://www.sciencedirect.com/science/article/abs/pii/S1087079207001682?via%3Dihub
- Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med. Jun 2006;7(4):312-8. doi:10.1016/j.sleep.2006.01.003. https://www.ncbi.nlm.nih.gov/pubmed/16709464 https://www.sciencedirect.com/science/article/abs/pii/S1389945706000104?via%3Dihub
- Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. Aug 15 2007;3(5):495-504. https://www.ncbi.nlm.nih.gov/pubmed/17803013 https://pmc.ncbi.nlm.nih.gov/articles/PMC1978328/
- Rajaratnam SM, Polymeropoulos MH, Fisher DM, et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet. Feb 7 2009;373(9662):482-91. doi:10.1016/S0140-6736(08)61812-7. https://www.ncbi.nlm.nih.gov/pubmed/19054552
- Ochoa-Sanchez R, Comai S, Lacoste B, et al. Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand. J Neurosci. Dec 14 2011;31(50):18439-52. doi:10.1523/JNEUROSCI.2676-11.2011. https://www.ncbi.nlm.nih.gov/pubmed/22171046
- Spadoni G, Bedini A, Rivara S, Mor M. Melatonin receptor agonists: new options for insomnia and depression treatment. CNS neuroscience & therapeutics. Dec 2011;17(6):733-41. doi:10.1111/j.1755-5949.2010.00197.x. https://www.ncbi.nlm.nih.gov/pubmed/21554566 https://pmc.ncbi.nlm.nih.gov/articles/PMC6493855/
- Posa L, De Gregorio D, Gobbi G, Comai S. Targeting Melatonin MT2 Receptors: A Novel Pharmacological Avenue for Inflammatory and Neuropathic Pain. Curr Med Chem. 2018;25(32):3866-3882. doi:10.2174/0929867324666170209104926. https://www.ncbi.nlm.nih.gov/pubmed/28183259 https://www.eurekaselect.com/article/81648
- Sangare A, Dubourget R, Geoffroy H, Gallopin T, Rancillac A. Serotonin differentially modulates excitatory and inhibitory synaptic inputs to putative sleep-promoting neurons of the ventrolateral preoptic nucleus. Neuropharmacology. Oct 2016;109:29-40. doi:10.1016/j.neuropharm.2016.05.015. https://www.ncbi.nlm.nih.gov/pubmed/27238836
- Nonogaki K. Serotonin conflict in sleep-feeding. Vitamins and hormones. 2012;89:223-39. doi:10.1016/B978-0-12-394623-2.00012-3. https://www.ncbi.nlm.nih.gov/pubmed/22640616
- Landolt HP, Wehrle R. Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood? Eur J Neurosci. May 2009;29(9):1795-809. doi:10.1111/j.1460-9568.2009.06718.x. https://www.ncbi.nlm.nih.gov/pubmed/19473234
- Nakamaru-Ogiso E, Miyamoto H, Hamada K, Tsukada K, Takai K. Novel biochemical manipulation of brain serotonin reveals a role of serotonin in the circadian rhythm of sleep-wake cycles. Eur J Neurosci. Jun 2012;35(11):1762-70. doi:10.1111/j.1460-9568.2012.08077.x. https://www.ncbi.nlm.nih.gov/pubmed/22625848
- Al-Shamma HA, Anderson C, Chuang E, et al. Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia. The Journal of pharmacology and experimental therapeutics. Jan 2010;332(1):281-90. doi:10.1124/jpet.109.160994. https://www.ncbi.nlm.nih.gov/pubmed/19841476
- Xiong Y, Ullman B, Choi JS, et al. Synthesis and in vivo evaluation of phenethylpiperazine amides: selective 5-hydroxytryptamine(2A) receptor antagonists for the treatment of insomnia. J Med Chem. Aug 12 2010;53(15):5696-706. doi:10.1021/jm100479q. https://www.ncbi.nlm.nih.gov/pubmed/20684606
- Song J, Um YH, Kim TW, Kim SM, Kwon SY, Hong S-C. Sleep and Anesthesia. Sleep Medicine Research. 6 2018;9(1):11-19. doi:10.17241/smr.2018.00164. https://doi.org/10.17241/smr.2018.00164 http://www.sleepmedres.org/journal/view.php?number=107 https://www.sleepmedres.org/upload/pdf/smr-2018-00164.pdf
- Dispersyn G, Pain L, Touitou Y. Propofol anesthesia significantly alters plasma blood levels of melatonin in rats. Anesthesiology. Feb 2010;112(2):333-7. doi:10.1097/ALN.0b013e3181c920e2. https://www.ncbi.nlm.nih.gov/pubmed/20098135
- Ortiz-Placin C, Salido GM, Gonzalez A. Melatonin Interplay in Physiology and Disease-The Fountain of Eternal Youth Revisited. Biomolecules. May 8 2025;15(5)doi:10.3390/biom15050682. https://www.ncbi.nlm.nih.gov/pubmed/40427575
- Cardinali DP, Srinivasan V, Brzezinski A, Brown GM. Melatonin and its analogs in insomnia and depression. Journal of pineal research. May 2012;52(4):365-75. doi:10.1111/j.1600-079X.2011.00962.x. https://www.ncbi.nlm.nih.gov/pubmed/21951153
- Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8(5):e63773. doi:10.1371/journal.pone.0063773. https://www.ncbi.nlm.nih.gov/pubmed/23691095
- van Geijlswijk IM, van der Heijden KB, Egberts AC, Korzilius HP, Smits MG. Dose finding of melatonin for chronic idiopathic childhood sleep onset insomnia: an RCT. Psychopharmacology. Oct 2010;212(3):379-91. doi:10.1007/s00213-010-1962-0. https://www.ncbi.nlm.nih.gov/pubmed/20668840
- Lemoine P, Wade AG, Katz A, Nir T, Zisapel N. Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials. Integrated blood pressure control. 2012;5:9-17. doi:10.2147/IBPC.S27240. https://www.ncbi.nlm.nih.gov/pubmed/22346363
- Garfinkel D, Zorin M, Wainstein J, Matas Z, Laudon M, Zisapel N. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study. Diabetes, metabolic syndrome and obesity : targets and therapy. 2011;4:307-13. doi:10.2147/DMSO.S23904. https://www.ncbi.nlm.nih.gov/pubmed/21887103
- Burke CA, Nitti VW, Stothers L. Melatonin and melatonin receptor agonists in the treatment of nocturia: A systematic review. Neurourology and urodynamics. Apr 2024;43(4):826-839. doi:10.1002/nau.25443. https://www.ncbi.nlm.nih.gov/pubmed/38456646
- Cruz-Sanabria F, Bruno S, Crippa A, et al. Optimizing the Time and Dose of Melatonin as a Sleep-Promoting Drug: A Systematic Review of Randomized Controlled Trials and Dose-Response Meta-Analysis. Journal of pineal research. Aug 2024;76(5):e12985. doi:10.1111/jpi.12985. https://www.ncbi.nlm.nih.gov/pubmed/38888087
- Baron KG, Reid KJ, Kim T, et al. Circadian timing and alignment in healthy adults: associations with BMI, body fat, caloric intake and physical activity. International journal of obesity (2005). Feb 2017;41(2):203-209. doi:10.1038/ijo.2016.194. https://www.ncbi.nlm.nih.gov/pubmed/27795550
- Baron KG, Reid KJ, Wolfe LF, Attarian H, Zee PC. Phase Relationship between DLMO and Sleep Onset and the Risk of Metabolic Disease among Normal Weight and Overweight/Obese Adults. J Biol Rhythms. Feb 2018;33(1):76-83. doi:10.1177/0748730417745914. https://www.ncbi.nlm.nih.gov/pubmed/29262758
- Rosenwasser AM, Turek FW. Neurobiology of Circadian Rhythm Regulation. Sleep medicine clinics. Dec 2015;10(4):403-12. doi:10.1016/j.jsmc.2015.08.003. https://www.ncbi.nlm.nih.gov/pubmed/26568118
- Toh KL. Basic science review on circadian rhythm biology and circadian sleep disorders. Ann Acad Med Singap. Aug 2008;37(8):662-8. https://www.ncbi.nlm.nih.gov/pubmed/18797559
- Mohawk JA, Green CB, Takahashi JS. Central and peripheral circadian clocks in mammals. Annu Rev Neurosci. 2012;35:445-62. doi:10.1146/annurev-neuro-060909-153128. https://www.ncbi.nlm.nih.gov/pubmed/22483041 https://pmc.ncbi.nlm.nih.gov/articles/PMC3710582/
- Huang H, Li L, Shi W, et al. The Multifunctional Effects of Nobiletin and Its Metabolites In Vivo and In Vitro. Evidence-based complementary and alternative medicine : eCAM. 2016;2016:2918796. doi:10.1155/2016/2918796. https://www.ncbi.nlm.nih.gov/pubmed/27761146
- He B, Nohara K, Park N, et al. The Small Molecule Nobiletin Targets the Molecular Oscillator to Enhance Circadian Rhythms and Protect against Metabolic Syndrome. Cell metabolism. Apr 12 2016;23(4):610-21. doi:10.1016/j.cmet.2016.03.007. https://www.ncbi.nlm.nih.gov/pubmed/27076076
- Gile J, Scott B, Eckle T. The Period 2 Enhancer Nobiletin as Novel Therapy in Murine Models of Circadian Disruption Resembling Delirium. Critical care medicine. Jun 2018;46(6):e600-e608. doi:10.1097/CCM.0000000000003077. https://www.ncbi.nlm.nih.gov/pubmed/29489460 https://pmc.ncbi.nlm.nih.gov/articles/PMC5953804/
- Shinozaki A, Misawa K, Ikeda Y, et al. Potent Effects of Flavonoid Nobiletin on Amplitude, Period, and Phase of the Circadian Clock Rhythm in PER2::LUCIFERASE Mouse Embryonic Fibroblasts. PLoS One. 2017;12(2):e0170904. doi:10.1371/journal.pone.0170904. https://www.ncbi.nlm.nih.gov/pubmed/28152057
- Richard DM, Dawes MA, Mathias CW, Acheson A, Hill-Kapturczak N, Dougherty DM. L-Tryptophan: Basic Metabolic Functions, Behavioral Research and Therapeutic Indications. Int J Tryptophan Res. Mar 23 2009;2:45-60. doi:10.4137/ijtr.s2129. https://www.ncbi.nlm.nih.gov/pubmed/20651948 https://pmc.ncbi.nlm.nih.gov/articles/PMC2908021/
- Peuhkuri K, Sihvola N, Korpela R. Diet promotes sleep duration and quality. Nutr Res. May 2012;32(5):309-19. doi:10.1016/j.nutres.2012.03.009. https://www.ncbi.nlm.nih.gov/pubmed/22652369
- Paredes SD, Barriga C, Reiter RJ, Rodriguez AB. Assessment of the Potential Role of Tryptophan as the Precursor of Serotonin and Melatonin for the Aged Sleep-wake Cycle and Immune Function: Streptopelia Risoria as a Model. Int J Tryptophan Res. 2009;2:23-36. doi:10.4137/ijtr.s1129. https://www.ncbi.nlm.nih.gov/pubmed/22084580 https://pmc.ncbi.nlm.nih.gov/articles/PMC3195230/
- Hartmann E, Cravens J, List S. Hypnotic effects of L-tryptophan. Archives of general psychiatry. Sep 1974;31(3):394-7. doi:10.1001/archpsyc.1974.01760150098014. https://www.ncbi.nlm.nih.gov/pubmed/4370080 https://jamanetwork.com/journals/jamapsychiatry/article-abstract/491219
- Paredes SD, Marchena AM, Bejarano I, et al. Melatonin and tryptophan affect the activity-rest rhythm, core and peripheral temperatures, and interleukin levels in the ringdove: changes with age. The journals of gerontology Series A, Biological sciences and medical sciences. Mar 2009;64(3):340-50. doi:10.1093/gerona/gln054. https://www.ncbi.nlm.nih.gov/pubmed/19211547 https://pmc.ncbi.nlm.nih.gov/articles/PMC2654999/
- Hajak G, Huether G, Blanke J, et al. The influence of intravenous L-tryptophan on plasma melatonin and sleep in men. Pharmacopsychiatry. Jan 1991;24(1):17-20. doi:10.1055/s-2007-1014427. https://www.ncbi.nlm.nih.gov/pubmed/2011617 https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2007-1014427
- Silber BY, Schmitt JA. Effects of tryptophan loading on human cognition, mood, and sleep. Neuroscience and biobehavioral reviews. Mar 2010;34(3):387-407. doi:10.1016/j.neubiorev.2009.08.005. https://www.ncbi.nlm.nih.gov/pubmed/19715722 https://www.sciencedirect.com/science/article/abs/pii/S0149763409001171?via%3Dihub
- Lieberman HR, Agarwal S, Fulgoni VL, 3rd. Tryptophan Intake in the US Adult Population Is Not Related to Liver or Kidney Function but Is Associated with Depression and Sleep Outcomes. J Nutr. Dec 2016;146(12):2609S-2615S. doi:10.3945/jn.115.226969. https://www.ncbi.nlm.nih.gov/pubmed/27934652
- Bravo R, Matito S, Cubero J, et al. Tryptophan-enriched cereal intake improves nocturnal sleep, melatonin, serotonin, and total antioxidant capacity levels and mood in elderly humans. Age (Dordr). Aug 2013;35(4):1277-85. doi:10.1007/s11357-012-9419-5. https://www.ncbi.nlm.nih.gov/pubmed/22622709
- Fukushige H, Fukuda Y, Tanaka M, et al. Effects of tryptophan-rich breakfast and light exposure during the daytime on melatonin secretion at night. Journal of physiological anthropology. Nov 19 2014;33(1):33. doi:10.1186/1880-6805-33-33. https://www.ncbi.nlm.nih.gov/pubmed/25407790
- Razak MA, Begum PS, Viswanath B, Rajagopal S. Multifarious Beneficial Effect of Nonessential Amino Acid, Glycine: A Review. Oxid Med Cell Longev. 2017;2017:1716701. doi:10.1155/2017/1716701. https://www.ncbi.nlm.nih.gov/pubmed/28337245
- Yamadera W, Inagawa K, Chiba S, Bannai M, Takahashi M, Nakayama K. Glycine ingestion improves subjective sleep quality in human volunteers, correlating with polysomnographic changes. Sleep and Biological Rhythms. 2007;5(2):126-131. doi:10.1111/j.1479-8425.2007.00262.x. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1479-8425.2007.00262.x https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1479-8425.2007.00262.x?download=true
- Inagawa K, Hiraoka T, Kohda T, Yamadera W, Takahashi M. Subjective effects of glycine ingestion before bedtime on sleep quality. Sleep and Biological Rhythms. 2006;4(1):75-77. doi:10.1111/j.1479-8425.2006.00193.x. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1479-8425.2006.00193.x
- Bannai M, Kawai N, Ono K, Nakahara K, Murakami N. The effects of glycine on subjective daytime performance in partially sleep-restricted healthy volunteers. Frontiers in neurology. 2012;3:61. doi:10.3389/fneur.2012.00061. https://www.ncbi.nlm.nih.gov/pubmed/22529837
- Durlach J, Pages N, Bac P, Bara M, Guiet-Bara A. Biorhythms and possible central regulation of magnesium status, phototherapy, darkness therapy and chronopathological forms of magnesium depletion. Magnesium research : official organ of the International Society for the Development of Research on Magnesium. Mar 2002;15(1-2):49-66. https://www.ncbi.nlm.nih.gov/pubmed/12030424
- NIH. National Institutes of Health. Office of Dietary Supplements. Magnesium. Updated 6/2/2022. Accessed 6/26/2025, https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/
- Frank S, Gonzalez K, Lee-Ang L, Young MC, Tamez M, Mattei J. Diet and Sleep Physiology: Public Health and Clinical Implications. Mini Review. Frontiers in neurology. 2017-August-11 2017;8(393):393. doi:10.3389/fneur.2017.00393. https://www.ncbi.nlm.nih.gov/pubmed/28848491
- Grandner MA, Jackson N, Gerstner JR, Knutson KL. Dietary nutrients associated with short and long sleep duration. Data from a nationally representative sample. Appetite. May 2013;64:71-80. doi:10.1016/j.appet.2013.01.004. https://www.ncbi.nlm.nih.gov/pubmed/23339991 https://pmc.ncbi.nlm.nih.gov/articles/PMC3703747/
- Nielsen FH. Relation between Magnesium Deficiency and Sleep Disorders and Associated Pathological Changes. In: Watson RR, ed. Modulation of Sleep by Obesity, Diabetes, Age, and Diet. Academic Press; 2015:291-296.
- Omiya K, Akashi YJ, Yoneyama K, Osada N, Tanabe K, Miyake F. Heart-rate response to sympathetic nervous stimulation, exercise, and magnesium concentration in various sleep conditions. International journal of sport nutrition and exercise metabolism. Apr 2009;19(2):127-35. doi:10.1123/ijsnem.19.2.127. https://www.ncbi.nlm.nih.gov/pubmed/19478338 https://journals.humankinetics.com/abstract/journals/ijsnem/19/2/article-p127.xml
- Hornyak M, Voderholzer U, Hohagen F, Berger M, Riemann D. Magnesium therapy for periodic leg movements-related insomnia and restless legs syndrome: an open pilot study. Sleep. Aug 1 1998;21(5):501-5. doi:10.1093/sleep/21.5.501. https://www.ncbi.nlm.nih.gov/pubmed/9703590
- Rondanelli M, Opizzi A, Monteferrario F, Antoniello N, Manni R, Klersy C. The effect of melatonin, magnesium, and zinc on primary insomnia in long-term care facility residents in Italy: a double-blind, placebo-controlled clinical trial. J Am Geriatr Soc. Jan 2011;59(1):82-90. doi:10.1111/j.1532-5415.2010.03232.x. https://www.ncbi.nlm.nih.gov/pubmed/21226679
- Abumaria N, Yin B, Zhang L, et al. Effects of elevation of brain magnesium on fear conditioning, fear extinction, and synaptic plasticity in the infralimbic prefrontal cortex and lateral amygdala. J Neurosci. Oct 19 2011;31(42):14871-81. doi:10.1523/JNEUROSCI.3782-11.2011. https://www.ncbi.nlm.nih.gov/pubmed/22016520
- Slutsky I, Abumaria N, Wu LJ, et al. Enhancement of learning and memory by elevating brain magnesium. Neuron. Jan 28 2010;65(2):165-77. doi:10.1016/j.neuron.2009.12.026. https://www.ncbi.nlm.nih.gov/pubmed/20152124
- Prasad AS. Zinc is an Antioxidant and Anti-Inflammatory Agent: Its Role in Human Health. Frontiers in nutrition. 2014;1:14. doi:10.3389/fnut.2014.00014. https://www.ncbi.nlm.nih.gov/pubmed/25988117
- Cherasse Y, Urade Y. Dietary Zinc Acts as a Sleep Modulator. International journal of molecular sciences. Nov 5 2017;18(11):2334. doi:10.3390/ijms18112334. https://www.ncbi.nlm.nih.gov/pubmed/29113075
- Song CH, Kim YH, Jung KI. Associations of zinc and copper levels in serum and hair with sleep duration in adult women. Biol Trace Elem Res. Oct 2012;149(1):16-21. doi:10.1007/s12011-012-9398-5. https://www.ncbi.nlm.nih.gov/pubmed/22476977 https://link.springer.com/article/10.1007/s12011-012-9398-5
- Cherasse Y, Saito H, Nagata N, Aritake K, Lazarus M, Urade Y. Zinc-containing yeast extract promotes nonrapid eye movement sleep in mice. Mol Nutr Food Res. Oct 2015;59(10):2087-93. doi:10.1002/mnfr.201500082. https://www.ncbi.nlm.nih.gov/pubmed/26105624
- Kenda M, Kocevar Glavac N, Nagy M, Sollner Dolenc M. Medicinal Plants Used for Anxiety, Depression, or Stress Treatment: An Update. Molecules (Basel, Switzerland). Sep 15 2022;27(18)doi:10.3390/molecules27186021. https://www.ncbi.nlm.nih.gov/pubmed/36144755
- Shi Y, Dong JW, Zhao JH, Tang LN, Zhang JJ. Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence. Curr Neuropharmacol. May 2014;12(3):289-302. doi:10.2174/1570159X11666131227001243. https://www.ncbi.nlm.nih.gov/pubmed/24851093 https://pmc.ncbi.nlm.nih.gov/articles/PMC4023459/
- Kakehashi A, Kato A, Ishii N, et al. Valerian inhibits rat hepatocarcinogenesis by activating GABA(A) receptor-mediated signaling. PLoS One. 2014;9(11):e113610. doi:10.1371/journal.pone.0113610. https://www.ncbi.nlm.nih.gov/pubmed/25419570
- Taavoni S, Ekbatani N, Kashaniyan M, Haghani H. Effect of valerian on sleep quality in postmenopausal women: a randomized placebo-controlled clinical trial. Menopause (New York, NY). Sep 2011;18(9):951-5. doi:10.1097/gme.0b013e31820e9acf. https://www.ncbi.nlm.nih.gov/pubmed/21775910
- Choi HS, Ko BS, Kim HD, Hong KB, Suh HJ. Effect of Valerian/Hop Mixture on Sleep-Related Behaviors in Drosophila melanogaster. Biological & pharmaceutical bulletin. 2017;40(7):1101-1110. doi:10.1248/bpb.b17-00262. https://www.ncbi.nlm.nih.gov/pubmed/28674253
- Ziegler G, Ploch M, Miettinen-Baumann A, Collet W. Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia--a randomized, double-blind, comparative clinical study. European journal of medical research. Nov 25 2002;7(11):480-6. https://www.ncbi.nlm.nih.gov/pubmed/12568976
- Kelber O, Nieber K, Kraft K. Valerian: no evidence for clinically relevant interactions. Evidence-based complementary and alternative medicine : eCAM. 2014;2014:879396. 879396. doi:10.1155/2014/879396. https://www.ncbi.nlm.nih.gov/pubmed/25093031
- Fernandez-San-Martin MI, Masa-Font R, Palacios-Soler L, Sancho-Gomez P, Calbo-Caldentey C, Flores-Mateo G. Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med. Jun 2010;11(6):505-11. doi:10.1016/j.sleep.2009.12.009. https://www.ncbi.nlm.nih.gov/pubmed/20347389 https://www.sciencedirect.com/science/article/abs/pii/S1389945710001000?via%3Dihub
- Anderson GD, Elmer GW, Taibi DM, et al. Pharmacokinetics of valerenic acid after single and multiple doses of valerian in older women. Phytother Res. Oct 2010;24(10):1442-6. doi:10.1002/ptr.3151. https://www.ncbi.nlm.nih.gov/pubmed/20878691
- Chen JH, Chao YH, Lu SF, Shiung TF, Chao YF. The effectiveness of valerian acupressure on the sleep of ICU patients: a randomized clinical trial. International journal of nursing studies. Aug 2012;49(8):913-20. doi:10.1016/j.ijnurstu.2012.02.012. https://www.ncbi.nlm.nih.gov/pubmed/22391336 https://www.sciencedirect.com/science/article/abs/pii/S0020748912000570?via%3Dihub
- Sanchez-Ortuno MM, Belanger L, Ivers H, LeBlanc M, Morin CM. The use of natural products for sleep: A common practice? Sleep Med. Oct 2009;10(9):982-7. doi:10.1016/j.sleep.2008.10.009. https://www.ncbi.nlm.nih.gov/pubmed/19427262 https://www.sciencedirect.com/science/article/abs/pii/S138994570900063X?via%3Dihub
- Zick SM, Wright BD, Sen A, Arnedt JT. Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study. journal article. BMC Complement Altern Med. Sep 22 2011;11(1):78. doi:10.1186/1472-6882-11-78. https://www.ncbi.nlm.nih.gov/pubmed/21939549
- Srivastava JK, Shankar E, Gupta S. Chamomile: A herbal medicine of the past with bright future. Molecular medicine reports. Nov 1 2010;3(6):895-901. doi:10.3892/mmr.2010.377. https://www.ncbi.nlm.nih.gov/pubmed/21132119
- Amsterdam JD, Shults J, Soeller I, Mao JJ, Rockwell K, Newberg AB. Chamomile (Matricaria recutita) may provide antidepressant activity in anxious, depressed humans: an exploratory study. Alternative therapies in health and medicine. Sep-Oct 2012;18(5):44-9. https://www.ncbi.nlm.nih.gov/pubmed/22894890 https://pmc.ncbi.nlm.nih.gov/articles/PMC3600408/
- Chang SM, Chen CH. Effects of an intervention with drinking chamomile tea on sleep quality and depression in sleep disturbed postnatal women: a randomized controlled trial. J Adv Nurs. Feb 2016;72(2):306-15. doi:10.1111/jan.12836. https://www.ncbi.nlm.nih.gov/pubmed/26483209
- Adib-Hajbaghery M, Mousavi SN. The effects of chamomile extract on sleep quality among elderly people: A clinical trial. Complementary therapies in medicine. Dec 2017;35:109-114. doi:10.1016/j.ctim.2017.09.010. https://www.ncbi.nlm.nih.gov/pubmed/29154054 https://www.sciencedirect.com/science/article/abs/pii/S0965229917302601?via%3Dihub
- Abdullahzadeh M, Matourypour P, Naji SA. Investigation effect of oral chamomilla on sleep quality in elderly people in Isfahan: A randomized control trial. J Educ Health Promot. 2017;6:53. doi:10.4103/jehp.jehp_109_15. https://www.ncbi.nlm.nih.gov/pubmed/28616420
- Miroddi M, Calapai G, Navarra M, Minciullo PL, Gangemi S. Passiflora incarnata L.: ethnopharmacology, clinical application, safety and evaluation of clinical trials. Journal of ethnopharmacology. Dec 12 2013;150(3):791-804. doi:10.1016/j.jep.2013.09.047. https://www.ncbi.nlm.nih.gov/pubmed/24140586
- Nassiri-Asl M, Shariati-Rad S, Zamansoltani F. Anticonvulsant effects of aerial parts of Passiflora incarnata extract in mice: involvement of benzodiazepine and opioid receptors. BMC Complement Altern Med. Aug 8 2007;7:26. doi:10.1186/1472-6882-7-26. https://www.ncbi.nlm.nih.gov/pubmed/17686156
- Dhawan K, Kumar S, Sharma A. Comparative anxiolytic activity profile of various preparations of Passiflora incarnata linneaus: a comment on medicinal plants' standardization. Journal of alternative and complementary medicine (New York, NY). Jun 2002;8(3):283-91. doi:10.1089/10755530260127970. https://www.ncbi.nlm.nih.gov/pubmed/12165186
- Appel K, Rose T, Fiebich B, Kammler T, Hoffmann C, Weiss G. Modulation of the gamma-aminobutyric acid (GABA) system by Passiflora incarnata L. Phytother Res. Jun 2011;25(6):838-43. doi:10.1002/ptr.3352. https://www.ncbi.nlm.nih.gov/pubmed/21089181
- Maroo N, Hazra A, Das T. Efficacy and safety of a polyherbal sedative-hypnotic formulation NSF-3 in primary insomnia in comparison to zolpidem: a randomized controlled trial. Indian journal of pharmacology. Jan-Feb 2013;45(1):34-9. doi:10.4103/0253-7613.106432. https://www.ncbi.nlm.nih.gov/pubmed/23543804
- Fahami F, Asali Z, Aslani A, Fathizadeh N. A comparative study on the effects of Hypericum Perforatum and passion flower on the menopausal symptoms of women referring to Isfahan city health care centers. vol 15. 2010:202-7.
- Dhawan K, Dhawan S, Chhabra S. Attenuation of benzodiazepine dependence in mice by a tri-substituted benzoflavone moiety of Passiflora incarnata Linneaus: a non-habit forming anxiolytic. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. May-Aug 2003;6(2):215-22. https://www.ncbi.nlm.nih.gov/pubmed/12935433
- Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian journal of psychological medicine. Jul 2012;34(3):255-62. doi:10.4103/0253-7176.106022. https://www.ncbi.nlm.nih.gov/pubmed/23439798
- Archana R, Namasivayam A. Antistressor effect of Withania somnifera. Journal of ethnopharmacology. Jan 1999;64(1):91-3. doi:10.1016/s0378-8741(98)00107-x. https://www.ncbi.nlm.nih.gov/pubmed/10075127 https://www.sciencedirect.com/science/article/abs/pii/S037887419800107X?via%3Dihub
- Bhattacharya SK, Bhattacharya A, Sairam K, Ghosal S. Anxiolytic-antidepressant activity of Withania somnifera glycowithanolides: an experimental study. Phytomedicine. Dec 2000;7(6):463-9. doi:10.1016/S0944-7113(00)80030-6. https://www.ncbi.nlm.nih.gov/pubmed/11194174 https://www.sciencedirect.com/science/article/abs/pii/S0944711300800306?via%3Dihub
- Kumar A, Kalonia H. Protective effect of Withania somnifera Dunal on the behavioral and biochemical alterations in sleep-disturbed mice (Grid over water suspended method). Indian journal of experimental biology. Jun 2007;45(6):524-8. https://www.ncbi.nlm.nih.gov/pubmed/17585686
- Shah N, Singh R, Sarangi U, et al. Combinations of Ashwagandha leaf extracts protect brain-derived cells against oxidative stress and induce differentiation. PLoS One. 2015;10(3):e0120554. doi:10.1371/journal.pone.0120554. https://www.ncbi.nlm.nih.gov/pubmed/25789768
- Suke S, Ghosh T, Yadav C, Ahmed R, Banerjee B. Ashwagandha reverses the dieldrin-induced cognitive impairment by modulation of oxidative stress in rat brain. Short Communication. Pharmacognosy Research. January 1, 2019 2019;11(1):92-97. doi:10.4103/pr.pr_77_18. http://www.phcogres.com/article.asp?issn=0974-8490;year=2019;volume=11;issue=1;spage=92;epage=97;aulast=Ghosh https://www.phcogres.com/sites/default/files/PharmacognRes-11-1-92.pdf
- Deshpande A, Irani N, Balkrishnan R, Benny IR. A randomized, double blind, placebo controlled study to evaluate the effects of ashwagandha (Withania somnifera) extract on sleep quality in healthy adults. Sleep Med. Aug 2020;72:28-36. doi:10.1016/j.sleep.2020.03.012. https://www.ncbi.nlm.nih.gov/pubmed/32540634 https://www.sciencedirect.com/science/article/abs/pii/S1389945720301246?via%3Dihub
- Kumar A, Kalonia H. Effect of Withania somnifera on Sleep-Wake Cycle in Sleep-Disturbed Rats: Possible GABAergic Mechanism. Indian journal of pharmaceutical sciences. Nov 2008;70(6):806-10. doi:10.4103/0250-474X.49130. https://www.ncbi.nlm.nih.gov/pubmed/21369449 https://pmc.ncbi.nlm.nih.gov/articles/PMC3040882/
- Manchanda S, Mishra R, Singh R, Kaur T, Kaur G. Aqueous Leaf Extract of Withania somnifera as a Potential Neuroprotective Agent in Sleep-deprived Rats: a Mechanistic Study. Molecular neurobiology. May 2017;54(4):3050-3061. doi:10.1007/s12035-016-9883-5. https://www.ncbi.nlm.nih.gov/pubmed/27037574 https://link.springer.com/article/10.1007/s12035-016-9883-5
- Kaushik MK, Kaul SC, Wadhwa R, Yanagisawa M, Urade Y. Triethylene glycol, an active component of Ashwagandha (Withania somnifera) leaves, is responsible for sleep induction. PLoS One. 2017;12(2):e0172508. doi:10.1371/journal.pone.0172508. https://www.ncbi.nlm.nih.gov/pubmed/28207892
- Raines T, Jones P, Moe N, Duncan R, McCall S, Ceremuga TE. Investigation of the anxiolytic effects of luteolin, a lemon balm flavonoid in the male Sprague-Dawley rat. AANA journal. Feb 2009;77(1):33-6. https://www.ncbi.nlm.nih.gov/pubmed/19263826
- Weeks BS. Formulations of dietary supplements and herbal extracts for relaxation and anxiolytic action: Relarian. Med Sci Monit. Nov 2009;15(11):RA256-62. https://www.ncbi.nlm.nih.gov/pubmed/19865069 https://medscimonit.com/abstract/index/idArt/878231
- Kennedy DO, Little W, Scholey AB. Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (Lemon Balm). Psychosomatic medicine. Jul-Aug 2004;66(4):607-13. doi:10.1097/01.psy.0000132877.72833.71. https://www.ncbi.nlm.nih.gov/pubmed/15272110
- Awad R, Muhammad A, Durst T, Trudeau VL, Arnason JT. Bioassay-guided fractionation of lemon balm (Melissa officinalis L.) using an in vitro measure of GABA transaminase activity. Phytother Res. Aug 2009;23(8):1075-81. doi:10.1002/ptr.2712. https://www.ncbi.nlm.nih.gov/pubmed/19165747
- Noguchi-Shinohara M, Ono K, Hamaguchi T, et al. Pharmacokinetics, Safety and Tolerability of Melissa officinalis Extract which Contained Rosmarinic Acid in Healthy Individuals: A Randomized Controlled Trial. PLoS One. 2015;10(5):e0126422. doi:10.1371/journal.pone.0126422. https://www.ncbi.nlm.nih.gov/pubmed/25978046
- Cases J, Ibarra A, Feuillere N, Roller M, Sukkar SG. Pilot trial of Melissa officinalis L. leaf extract in the treatment of volunteers suffering from mild-to-moderate anxiety disorders and sleep disturbances. Med J Nutrition Metab. Dec 2011;4(3):211-218. doi:10.1007/s12349-010-0045-4. https://www.ncbi.nlm.nih.gov/pubmed/22207903
- Muller SF, Klement S. A combination of valerian and lemon balm is effective in the treatment of restlessness and dyssomnia in children. Phytomedicine. Jun 2006;13(6):383-7. doi:10.1016/j.phymed.2006.01.013. https://www.ncbi.nlm.nih.gov/pubmed/16487692
- Lillehei AS, Halcon LL, Savik K, Reis R. Effect of Inhaled Lavender and Sleep Hygiene on Self-Reported Sleep Issues: A Randomized Controlled Trial. Journal of alternative and complementary medicine (New York, NY). Jul 2015;21(7):430-8. doi:10.1089/acm.2014.0327. https://www.ncbi.nlm.nih.gov/pubmed/26133206 https://pmc.ncbi.nlm.nih.gov/articles/PMC4505755/
- Chien LW, Cheng SL, Liu CF. The effect of lavender aromatherapy on autonomic nervous system in midlife women with insomnia. Evidence-based complementary and alternative medicine : eCAM. 2012;2012:740813. doi:10.1155/2012/740813. https://www.ncbi.nlm.nih.gov/pubmed/21869900
- Conrad P, Adams C. The effects of clinical aromatherapy for anxiety and depression in the high risk postpartum woman - a pilot study. Complementary therapies in clinical practice. Aug 2012;18(3):164-8. doi:10.1016/j.ctcp.2012.05.002. https://www.ncbi.nlm.nih.gov/pubmed/22789792 https://www.sciencedirect.com/science/article/abs/pii/S1744388112000400?via%3Dihub
- Hirokawa K, Nishimoto T, Taniguchi T. Effects of lavender aroma on sleep quality in healthy Japanese students. Perceptual and motor skills. Feb 2012;114(1):111-22. doi:10.2466/13.15.PMS.114.1.111-122. https://www.ncbi.nlm.nih.gov/pubmed/22582680
- Koulivand PH, Khaleghi Ghadiri M, Gorji A. Lavender and the nervous system. Evidence-based complementary and alternative medicine : eCAM. 2013;2013:681304. doi:10.1155/2013/681304. https://www.ncbi.nlm.nih.gov/pubmed/23573142
- Woelk H, Schlafke S. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. Phytomedicine. Feb 2010;17(2):94-9. doi:10.1016/j.phymed.2009.10.006. https://www.ncbi.nlm.nih.gov/pubmed/19962288 https://www.sciencedirect.com/science/article/abs/pii/S094471130900261X?via%3Dihub
- Christodoulou E, Kadoglou NP, Kostomitsopoulos N, Valsami G. Saffron: a natural product with potential pharmaceutical applications. The Journal of pharmacy and pharmacology. Dec 2015;67(12):1634-49. doi:10.1111/jphp.12456. https://www.ncbi.nlm.nih.gov/pubmed/26272123
- Broadhead GK, Chang A, Grigg J, McCluskey P. Efficacy and Safety of Saffron Supplementation: Current Clinical Findings. Crit Rev Food Sci Nutr. Dec 9 2016;56(16):2767-76. doi:10.1080/10408398.2013.879467. https://www.ncbi.nlm.nih.gov/pubmed/25875654
- Soeda S, Aritake K, Urade Y, Sato H, Shoyama Y. Neuroprotective Activities of Saffron and Crocin. Advances in neurobiology. 2016;12:275-92. doi:10.1007/978-3-319-28383-8_14. https://www.ncbi.nlm.nih.gov/pubmed/27651258 https://link.springer.com/chapter/10.1007/978-3-319-28383-8_14
- Liu Z, Xu XH, Liu TY, et al. Safranal enhances non-rapid eye movement sleep in pentobarbital-treated mice. CNS neuroscience & therapeutics. Aug 2012;18(8):623-30. doi:10.1111/j.1755-5949.2012.00334.x. https://www.ncbi.nlm.nih.gov/pubmed/22632633 https://pmc.ncbi.nlm.nih.gov/articles/PMC6493539/
- Dehghanmehr S, Shadadi H, Mansouri A, Arbabisarjou A, et al. Effect of oral saffron capsules on sleep quality in patients with diabetes at Zabol-Iran. Bali Medical Journal. 2017;6(3):595. doi:10.15562/bmj.v6i3.623. https://pdfs.semanticscholar.org/dc51/b27ca0ce772fca77485e30616185d35aaee4.pdf https://www.balimedicaljournal.org/index.php/bmj/article/download/623/pdf_308
- Alexeev M, Grosenbaugh DK, Mott DD, Fisher JL. The natural products magnolol and honokiol are positive allosteric modulators of both synaptic and extra-synaptic GABA(A) receptors. Neuropharmacology. Jun 2012;62(8):2507-14. doi:10.1016/j.neuropharm.2012.03.002. https://www.ncbi.nlm.nih.gov/pubmed/22445602 https://pmc.ncbi.nlm.nih.gov/articles/PMC3652012/
- Arora S, Singh S, Piazza GA, Contreras CM, Panyam J, Singh AP. Honokiol: a novel natural agent for cancer prevention and therapy. Current molecular medicine. Dec 2012;12(10):1244-52. doi:10.2174/156652412803833508. https://www.ncbi.nlm.nih.gov/pubmed/22834827 https://pmc.ncbi.nlm.nih.gov/articles/PMC3663139/
- Talarek S, Listos J, Barreca D, et al. Neuroprotective effects of honokiol: from chemistry to medicine. BioFactors (Oxford, England). Nov 2017;43(6):760-769. doi:10.1002/biof.1385. https://www.ncbi.nlm.nih.gov/pubmed/28817221
- Qu WM, Yue XF, Sun Y, et al. Honokiol promotes non-rapid eye movement sleep via the benzodiazepine site of the GABA(A) receptor in mice. Br J Pharmacol. Oct 2012;167(3):587-98. doi:10.1111/j.1476-5381.2012.02010.x. https://www.ncbi.nlm.nih.gov/pubmed/22537192
- Kuribara H, Kishi E, Hattori N, Okada M, Maruyama Y. The anxiolytic effect of two oriental herbal drugs in Japan attributed to honokiol from magnolia bark. The Journal of pharmacy and pharmacology. Nov 2000;52(11):1425-9. doi:10.1211/0022357001777432. https://www.ncbi.nlm.nih.gov/pubmed/11186252
- Kuribara H, Stavinoha WB, Maruyama Y. Behavioural pharmacological characteristics of honokiol, an anxiolytic agent present in extracts of Magnolia bark, evaluated by an elevated plus-maze test in mice. The Journal of pharmacy and pharmacology. Jul 1998;50(7):819-26. doi:10.1111/j.2042-7158.1998.tb07146.x. https://www.ncbi.nlm.nih.gov/pubmed/9720634
- Kuribara H, Stavinoha WB, Maruyama Y. Honokiol, a putative anxiolytic agent extracted from magnolia bark, has no diazepam-like side-effects in mice. The Journal of pharmacy and pharmacology. Jan 1999;51(1):97-103. https://www.ncbi.nlm.nih.gov/pubmed/10197425
- Wang L, Ma R, Liu C, et al. Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases. Curr Pharm Des. 2017;23(7):1077-1097. doi:10.2174/1381612822666161010105242. https://www.ncbi.nlm.nih.gov/pubmed/27748194 https://pmc.ncbi.nlm.nih.gov/articles/PMC5421141/
- Lai XJ, Zhang L, Li JS, et al. Comparative pharmacokinetic and bioavailability studies of three salvianolic acids after the administration of Salviae miltiorrhizae alone or with synthetical borneol in rats. Fitoterapia. Sep 2011;82(6):883-8. doi:10.1016/j.fitote.2011.04.015. https://www.ncbi.nlm.nih.gov/pubmed/21575691
- Huiyun Z, Rong O. THE INHIBITORY EFFECT OF SALVIA MILTRIORRHIZA BGE ON THE CENTRAL NERVOUS SYSTEM [J]. Acta Pharmaceutica Sinica. 1979;5
- Kim JH, Desor D, Kim YT, et al. Efficacy of alphas1-casein hydrolysate on stress-related symptoms in women. European journal of clinical nutrition. Apr 2007;61(4):536-41. doi:10.1038/sj.ejcn.1602553. https://www.ncbi.nlm.nih.gov/pubmed/17136040 https://www.nature.com/articles/1602553
- de Saint-Hilaire ZM, M.; Desor, D.; Kobayashi, T. Effects of a Bovine Alpha S1-Casein Tryptic Hydrolysate (CTH) on Sleep Disorder in Japanese General Population. Open Sleep J. 2009;2:26–32. https://benthamopenarchives.com/abstract.php?ArticleCode=TOSLPJ-2-26
- Cicero AFG, Allkanjari O, Busetto GM, et al. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. Arch Ital Urol Androl. Oct 2 2019;91(3)doi:10.4081/aiua.2019.3.139. https://www.ncbi.nlm.nih.gov/pubmed/31577095
- Li Y, Zhou X, Qiu S, et al. Association of sleep quality with lower urinary tract symptoms/benign prostatic hyperplasia among men in China: A cross-sectional study. Frontiers in aging neuroscience. 2022;14:938407. doi:10.3389/fnagi.2022.938407.
- Ma K, Dong Q. Association between sleep quality and benign prostate hyperplasia among middle-aged and older men in India. BMC Public Health. 2023/06/14 2023;23(1):1147. doi:10.1186/s12889-023-15972-6. https://doi.org/10.1186/s12889-023-15972-6
- Liu X, Sun P, Bao X, Cao Y, Wang L, Wang Q. Potential mechanisms of traditional Chinese medicine in treating insomnia: A network pharmacology, GEO validation, and molecular-docking study. Medicine. May 3 2024;103(18):e38052. doi:10.1097/MD.0000000000038052. https://www.ncbi.nlm.nih.gov/pubmed/38701256
- Schoendorfer N, Sharp N, Seipel T, Schauss AG, Ahuja KDK. Urox containing concentrated extracts of Crataeva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root, in the treatment of symptoms of overactive bladder and urinary incontinence: a phase 2, randomised, double-blind placebo controlled trial. BMC Complement Altern Med. Jan 31 2018;18(1):42. doi:10.1186/s12906-018-2101-4. https://www.ncbi.nlm.nih.gov/pubmed/29385990
- Rohrmann S, Smit E, Giovannucci E, Platz EA, Third National H, Nutrition Examination S. Association between serum concentrations of micronutrients and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey. Urology. Sep 2004;64(3):504-9. doi:10.1016/j.urology.2004.04.012. https://www.ncbi.nlm.nih.gov/pubmed/15351580
- Beydoun MA, Gamaldo AA, Canas JA, et al. Serum nutritional biomarkers and their associations with sleep among US adults in recent national surveys. PLoS One. 2014;9(8):e103490. doi:10.1371/journal.pone.0103490. https://www.ncbi.nlm.nih.gov/pubmed/25137304
- Grandner MA, Jackson N, Gerstner JR, Knutson KL. Sleep symptoms associated with intake of specific dietary nutrients. J Sleep Res. Feb 2014;23(1):22-34. doi:10.1111/jsr.12084. https://www.ncbi.nlm.nih.gov/pubmed/23992533 https://pmc.ncbi.nlm.nih.gov/articles/PMC3866235/
- Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G. Pygeum africanum for benign prostatic hyperplasia. The Cochrane database of systematic reviews. 2002;1998(1):CD001044. doi:10.1002/14651858.CD001044. https://www.ncbi.nlm.nih.gov/pubmed/11869585 https://pmc.ncbi.nlm.nih.gov/articles/PMC7032619/